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ABSTRACT 
English 
Streptococcus pneumoniae is one of the major causes of bacterial meningitis, which mainly 
affects young infants in the developing countries of Africa, Asia (esp. India) and South 
America, and which has case fatality rates up to 50% in those regions. Bacterial meningitis 
comprises an infection of the meninges and the sub-meningeal cortex tissue of the brain, 
whereat the presence of pneumolysin (PLY), a major virulence factor of the pneumococcus, is 
prerequisite for the development of a severe outcome of the infection and associated tissue 
damage (e. g. apoptosis, brain edema, and ischemia). Pneumolysin belongs to the family of 
pore forming, cholesterol-dependent cytolysins (CDCs), bacterial protein toxins, which 
basically use membrane-cholesterol as receptor and oligomerize to big aggregates, which 
induce cell lysis and cell death by disturbance of membrane integrity. 
Multiple recent studies, including this work, have revealed a new picture of pneumolysin, 
whose cell-related properties go far beyond membrane binding, pore formation and the 
induction of cell death and inflammatory responses. For a long time, it has been known that 
bacteria harm the tissues of their hosts in order to promote their own survival and 
proliferation. Many bacterial toxins aim to rather hijack cells than to kill them, by interacting 
with cellular components, such as the cytoskeleton or other endogenous proteins. This study 
was able to uncover a novel capacity of pneumolysin to interact with components of the actin 
machinery and to promote rapid, actin-dependent cell shape changes in primary astrocytes. 
The toxin was applied in disease-relevant concentrations, which were verified to be sub-lytic. 
These amounts of toxin induced a rapid actin cortex collapse in horizontal direction towards 
the cell core, whereat membrane integrity was preserved, indicating an actin severing function 
of pneumolysin, and being consistent with cell shrinkage, displacement, and blebbing observed 
in live cell imaging experiments. 
In contrast to neuroblastoma cells, in which pneumolysin led to cytoskeleton remodeling and 
simultaneously to activation of Rac1 and RhoA, in primary astrocytes the cell shape changes 
were seen to be primarily independent of small GTPases. The level of activated Rac1 and RhoA 
did not increase at the early time points after toxin application, when the initial shape changes 
have been observed, but at later time points when the actin-dependent displacement of cells 
was slower and less severe, probably presenting the cell‟s attempt to re-establish proper 
cytoskeleton function.  
A GUV (giant unilamellar vesicle) approach provided insight into the effects of pneumolysin in 
a biomimetic system, an environment, which is strictly biochemical, but still comprises cellular 
components, limited to the factors of interest (actin, Arp2/3, ATP, and Mg2+ on one side, and 
PLY on the other side). This approach was able to show that the wildtype-toxin, but not the Δ6 
mutant (mutated in the unfolding domain, and thus non-porous), had the capacity to exhibit 
its functions through a membrane bilayer, meaning it was able to aggregate actin, which was 
located on the other side of the membrane, either via direct interaction with actin or in an 
Arp2/3 activating manner.  
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Taking a closer look at these two factors with the help of several different imaging and 
biochemical approaches, this work unveiled the capacity of pneumolysin to bind and interact 
both with actin and Arp2 of the Arp2/3 complex. Pneumolysin was capable to slightly stabilize 
actin in an actin-pyrene polymerization assay. The same experimental setup was applied to 
show that the toxin had the capacity to lead to actin polymerization through activation of the 
Arp2/3 complex. This effect was additionally confirmed with the help of fluorescent microscopy 
of rhodamine (TRITC)-tagged actin. Strongest Arp2/3 activation, and actin 
nucleation/polymerization is achieved by the VCA domain of the WASP family proteins. 
However, addition of PLY to the Arp2/3–VCA system led to an enhanced actin nucleation, 
suggesting a synergistic activation function of pneumolysin. 
Hence, two different effects of pneumolysin on the actin cytoskeleton were observed. On the 
one hand an actin severing property, and on the other hand an actin stabilization property, 
both of which do not necessarily exclude each other. 
Actin remodeling is a common feature of bacterial virulence strategies. This is the first time, 
however, that these properties were assigned to a toxin of the CDC family. Cytoskeletal 
dysfunction in astrocytes leads to dysfunction and unregulated movement of these cells, 
which, in context of bacterial meningitis, can favor bacterial penetration and spreading in the 
brain tissue, and thus comprises an additional role of pneumolysin as a virulence factor of 
Streptococcus pneumonia in the context of brain infection. 
The aim of this study was to gain clarification of exact molecular mechanisms of cytoskeletal 
modifications. These findings in turn are prerequisite for the future development of efficient 
therapeutic approaches in order to better control the spreading and lethality of one major 
threat to a high number of people at risk of infection and little access to prevention. 
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Deutsch 
Streptococcus pneumoniae gehört zur Gruppe der Pathogene, die bakterielle Meningitis 
verursachen, eine Infektion, die hauptsächlich bei Neugeborenen und Kleinkindern in den 
Entwicklungsländern von Afrika, Asien (Indien) und Südamerika auftritt, und in diesen 
Regionen Sterblichkeitsraten von bis zu 50% aufweist. Meningitis ist eine Infektion der 
Hirnhäute und dem sich direkt darunter befindlichen Cortex-Gewebe. Pneumolysin (PLY), ein 
Haupt-Pathogenitätsfaktor des sog. Pneumococcus, ist hauptsächlich verantwortlich für einen 
schweren Verlauf der Infektion und für Gewebeschädigungen, wie Apoptose, Hirnödemen und 
Ischämie. 
Pneumolysin gehört zur Familie der Cholesterol-abhängigen Cytolysine (CDCs), bakteriellen 
Protein-Toxinen, die an Membran-Cholesterol binden, sich zu großen Aggregaten 
zusammenschließen und durch die Beeinträchtigung der Membranintegrität (Porenbildung) 
Zell-Lyse und Zelltod verursachen. 
Zahlreiche neuere Studien, darunter auch diese Arbeit, haben ein neues Bild von Pneumolysin 
aufgezeigt, dessen Eigenschaften weit über die Membranbindung, die Poren-Bildung und die 
Induktion von Zelltod und inflammatorischen Prozessen hinausgehen. Es ist weithin bekannt, 
dass Bakterien das Gewebe ihres Wirts schädigen, um ihre eigene Vermehrung und ihre 
Ausbreitung zu begünstigen. In diesem Zusammenhang fungieren bakterielle Toxine als 
Pathogenitätsfaktoren, die mit zellulären Komponenten, wie dem Zytoskelett und anderen 
Zytosol-Proteinen interagieren, was allerdings bevorzugt zu Zellveränderungen, und seltener 
zum Zelltod führt. 
Die vorliegende Arbeit konnte zeigen, dass Pneumolysin schnelle, und zum Teil gravierende, 
Aktin-abhängige Zellstruktur-Veränderungen in primären Astrozyten hervorruft. Hierbei wurde 
das Toxin in Konzentrationen appliziert, die im Liquor von Meningitis-Patienten detektiert 
werden können, und die zusätzlich als sub-lytisch für Astrozyten in Zellkultur verifiziert 
wurden. Diese Toxin-Mengen führten zu einem schnellen, horizontalen Aktinkortex-Kollaps, 
wobei die Membranintegrität erhalten blieb. Dies deutete auf eine „Severing“-Funktion (das 
Abtrennen oder Zerschneiden von Aktinfilamenten) von Pneumolysin hin, was mit den 
Beobachtungen übereinstimmt, die in Experimenten mit lebendigen Zellen gemacht wurden 
(Zellveränderungen, Zellbewegungen und „Blebbings“). 
Im Gegensatz zu Neuroblastoma Zellen, in denen Pneumolysin Zytoskelett-Veränderungen, 
und gleichzeitig die Aktivierung von Rac1 und RhoA verursachte, waren die Zell-
Veränderungen bei Astrozyten primär unabhängig von der Aktivierung kleiner GTPasen. 
Obwohl gezeigt werden konnte, dass die Veränderungen vom Aktin-Zytosklett abhängig 
waren, war das Level an Rac1 und RhoA in den frühen Phasen nach der Toxin-Gabe nicht 
erhöht. Eine Aktivierung der GTPasen konnte dahingegen zu späteren Zeitpunkten detektiert 
werden, in denen die Zellbewegung abgeschwächt und verlangsamt war. Die späte Aktivierung 
kann als Reaktion der Zelle auf die vom Toxin ausgelösten Veränderungen gesehen werden, 
die zu einer Wiederherstellung der normalen Zytoskelett-Funktion führen soll. 
GUV (giant unilamellar vesicle)-Experimente ermöglichten eine genauere Betrachtung der 
Pneumolysin-Effekte in einem biomimetischen, jedoch strikt biochemischen Ansatz, der alle 
zellulären Komponenten enthält, die untersucht werden sollen (Pneumolysin, Aktin, Arp2/3, 
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ATP, und Mg2+ ). Im GUV-System befand sich das Toxin im Inneren der Vesikel, und Aktin in 
der extra-vesikulären Suspension, einem Verhältnis genau umgekehrt zum zellullären System. 
Zusätzlich wurden Arp2/3 und ATP/Mg2+, für die Aktin-Polymerisierung essentielle Faktoren, in 
der Aktin-Suspension zur Verfügung gestellt. Die GUV-Experimente konnten zeigen, dass 
Wildtyp-Pneumolysin, allerdings nicht seine Mutante Δ6-PLY (Mutation in der sog. unfolding 
domain, und deshalb nicht Poren-bildend), seine Effekte auf das Aktin-Zytoskelett durch die 
Membran-Barriere hindurch, in einer Membran-gebundenen Form ausüben kann. Aktin wurde 
an den Stellen höchster Toxinbindung aggregiert, was entweder über eine direkte Interaktion 
von PLY mit Aktin, oder über eine Aktivierung des Aktin-Effektors Arp2/3 durch Pneumolysin 
erklärt werden kann. 
Weitere biochemische Ansätze (wie enzyme-linked sorbent assays, ELSAs) und Mikroskopie-
Techniken (Immunocyto-Chemie) konnten beweisen, dass Pneumolysin sowohl mit Aktin, als 
auch mit Arp2 (einer Komponente des heptameren Arp2/3 Proteinkomplexes) direkt 
interagieren kann. Aktin-Pyren Experimente und Fluoreszenzmikroskopie (von TRITC-
markiertem Aktin) wiesen auf eine Kapazität von Pneumolysin hin, Aktin direkt zu stabilisieren, 
und über die Aktivierung von Arp2/3 eine Aktin-Polymerisierung hervorrufen zu können. Der 
zelluläre Aktivator von Arp2/3 ist die VCA-Domäne von sog. WAS (Wiskott-Aldrich-syndrome)-
Proteinen. VCA induziert eine Arp2/3-abhängige Aktin-Nukleierung, was zu einer schnellen 
Aktin-Polymerisierung führt. In diesem System erzeugte die Zugabe von Pneumolysin eine 
Verstärkung der Aktin-Nukleierung (synergistische Wirkung). 
Demzufolge konnten in dieser Arbeit zwei abweichende Effekte von Pneumolysin auf das Aktin-
Zytoskelett aufgezeigt werden. Einerseits zeigte das Toxin die Fähigkeit, den Aktinkortex von 
der Plasmamembran zu lösen („Severing“), und andererseits induzierte Pneumolysin eine 
Aktin-Stabilisierung, wobei sich beide Phänomene nicht grundsätzlich ausschließen. 
Bakterielle Effektoren wirken häufig spezifisch auf das Aktin-Zytoskelett der Zellen im Gewebe 
des Wirts. In dieser Arbeit wurden diese Eigenschaften jedoch zum ersten Mal für ein Toxin der 
CDC-Familie vorgeschlagen. Eine Dysfunktion von Aktin in Astrozyten führt zu einer generellen 
Dysfunktion und zu einer unkoordinierten Bewegung der Zellen, was im Kontext von 
bakterieller Meningitis zu einer verstärkten bakteriellen Penetration und Ausbreitung im 
Hirngewebe des Wirtes führen kann, und somit zusätzlich die Rolle von Pneumolysin als 
Pathogenitätsfaktor von Streptococcus pneumoniae im Kontext von Infektionen des Gehirns 
bekräftigt. 
Das Ziel dieser Arbeit, die molekularen Grundlagen der Pneumolysin-induzierten Zytoskelett-
Veränderungen aufzuzeigen, ist Voraussetzung für die Entwicklung von effizienten 
therapeutischen Ansätzen, um die Ausbreitung und die Lethalität eines Pathogens zu 
kontrollieren, das im Besonderen eine große Anzahl von Menschen bedroht, die nur begrenzt 
Zugang zu Prävention und Behandlung haben. 
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1 INTRODUCTION 
1.1 Streptococcus pneumoniae 
Bacteria of the genus Streptococcus are Gram-positive, alpha-hemolytic, catalase-negative, 
anaerobic, but aero-tolerant. In Gram staining the organism appears as pairs of short chains of 
cocci (Fig. 1) [Kayser, 1998]. It was identified by Louis Pasteur in 1881 and given the name 
pneumococcus in the 1880s, as it was the most common cause of pneumonia [Marriott and 
Dockrell, 2006].  
 
 
 
Fig. 1: S. pneumoniae (electron microscopy). 
The Gram-positive pneumococcus appears as pairs of 
short chains of cocci in EM and Gram staining. 
(Source: http://phil.cdc.gov, by R. Facklam, 2009; 
2011) 
 
 
S. pneumoniae is a commensal of the human upper airways, and becomes infectious only 
under immuno-suppressed conditions of the organism, and under conditions of gaining access 
to normally sterile spaces like the brain or bloodstream. However, colonization is the initial 
step in pathogenesis of all pneumococcal infections [Bogaert et al., 2004], whereat 
S. pneumoniae comprises a classical extracellular bacterium, as it is poorly opsonized and thus 
barely phagocytosed [Marriott and Dockrell, 2006]. 
Especially young children, elderly people, alcoholics, and patients with chronic disorders, such 
as HIV/AIDS, are susceptive to S. pneumoniae related conditions, such as pneumonia, 
bacteremia, sepsis, Otitis media and meningitis. 
Pneumococcus expresses a variety of colonization and virulence factors (as shown in Table 1), 
including a polysaccharide capsule, surface proteins and enzymes, an autolysin, and the 
cytolysin pneumolysin (PLY) (reviewed in [Mitchell and Mitchell, 2010]). Up to date 90 different 
serotypes of S. pneumoniae are known, which are distinguished by capsular polysaccharide 
antigens [Henrichsen, 1995].  
 
 
1.2 Bacterial meningitis 
1.2.1 Epidemiology 
Bacterial meningitis comprises an acute infection of the protective membranes covering the 
brain and spinal cord, the so-called meninges (Fig. 2) and the cortex tissue below the 
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meninges. Brain tissue changes accompany the course of infections of the brain. They include 
brain swelling and perivascular and perimeningeal extracellular matrix digestion (most likely 
originating from the infiltrating leucocytes) [Kastenbauer and Pfister, 2003; Liu et al., 2008; 
Pfister et al., 1993].  
Bacterial meningitis remains, despite of the availability of vaccination and antibiotic treatment, 
a threat to global health, causing death of estimated 170,000 infected worldwide per year 
(source: World Health Organization 2011).  
 
 
 
Fig. 2: The meninges. 
The mammalian brain is covered by three protective 
layers. Meningitis is an acute infection of those layers 
and the closely associated cortex tissue directly below. 
(Source: Yale School of Medicine; 
http://medicalcenter.osu.edu; 2011) 
 
 
Large-scale epidemics occur especially in the African Sub-Saharan “meningitis belt” (Fig. 3) 
and widespread in India, but also in countries with high medical standards, pneumococcal 
infections come along with severe complications. Acute meningitis leads to death in about 33% 
of cases. More than 20% of surviving patients suffer from residual neurological symptoms 
(WHO 1997), such as mental retardation, learning disabilities and focal neurological deficits 
(e. g. hearing loss) (reviewed in [Bohr et al., 1984]). Under acute infectious conditions blood 
vessel inflammation, necrosis of the central nervous system (CNS), neuronal loss, general 
inflammation of brain tissue, and coma are common complications (further details in [Cairns 
and Russell, 1946]). 
Most cases of meningitis are caused by the three bacterial species Haemophilus influenzae 
(Hib), Streptococcus pneumoniae, and Neisseria meningitidis. Since the introduction of Hib 
conjugate vaccines, N. meningitidis and S. pneumoniae have become the main causative 
agents of bacterial meningitis (WHO 2011). Latter is the primary factor for outbreak in children 
younger than one year of age (particularly during the neonatal period), and the second 
frequent cause in older children [Bingen et al., 2005].  Besides meningitis, S. pneumoniae 
causes pneumonia, Otitis media, and sepsis. All infections caused by pneumococcus comprise 
complications especially during early childhood. Recent estimates of child deaths caused by 
this pathogen range from 700,000 to 1 million every year worldwide [WHO, 1999, 2003, 
2007]. 
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Fig. 3: Distribution of meningitis cases in 2002. 
A. Streptococcus pneumoniae incidence rate per 100,000 children under five years of age in 2000. In 
Africa most cases occur within the so called “meningitis belt”, reaching from Senegal in the West to 
Ethiopia in the East.  
B. Mortality rate per 100,000 children under five years of age due to Streptococcus pneumoniae, 2000 in 
Africa (modified). (Source: WHO, 2000; 2011) 
 
 
1.2.2 Prevention and treatment 
A 7-valent conjugate vaccine (PCV7), and a recently introduced 13-valent variant (PCV13) are 
available for prevention of invasive pneumococcal diseases (IPD), based on a reduction of 
nasopharyngeal carriage of S. pneumoniae among immunized children, which in turn 
decreases transmission to non-immunized persons [Rubin et al., 2010]. Availability of 
preventive procedure, however, is mainly restricted to developed countries, whereas the 
epidemic centers in Africa and India can only be covered punctually by special vaccination 
campaigns (WHO, 2011).  
Increasing resistance against the first choice antibiotic penicillin complicates and raises costs of 
treatment of meningitis. Additional regimens with vancomycin plus a third-generation 
cephalosporin have become necessary [Bingen et al., 2008]. 
 
 
1.3 Pneumolysin - a bacterial protein toxin 
1.3.1 Pore-forming toxins 
Toxins are often defined as bacterial effectors that can act in the absence of the bacteria. 
Other bacterial effectors, in contrast, depend on delivery into the host, and thus on the 
presence of the pathogen (reviewed in [Aktories et al., 2011]). 
Pore-forming protein toxins are an aggressive approach of pathogens, meant to enter, to 
damage/destroy, or to manipulate host cells for their own advantage. Those proteins 
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encounter biological membranes and are known to lead to either membrane collapse, or to 
induction of signaling events downstream of membrane binding events, e. g. activation of 
small GTPases (reviewed in [Aktories and Barbieri, 2005]). Pore-forming proteins were 
identified in a wide range of organisms, including bacteria, plants, fungi, and even animals 
[Iacovache et al., 2008]. 
 
 
1.3.2 Pneumolysin - a member of the CDC family 
The protein toxin pneumolysin (PLY) (471 amino acids, 53kD) represents one of the major 
virulence factors of Streptococcus pneumoniae. It belongs to the family of cholesterol-
dependent cytolysins (CDCs), β-barrel pore forming toxins, secreted by Gram-positive bacteria 
via a - for S. pneumoniae - not yet verified mechanism [Jefferies et al., 2007; Marriott et al., 
2008]. 
The toxins are released as water soluble monomers, that recognize cholesterol as a receptor 
on the target membrane, bind and oligomerize to characteristic arcs and ring-like structures 
(about 30-50 monomers), representing cell lysis inducing pores (with a diameter of about 
260 Å) (reviewed in [Alouf, 2000; Giddings et al., 2003; Tweten, 2005]).  
The pore forming event includes the insertion of two amphipathic β-hairpins from each of the 
~35 monomers and spanning of the membrane via dramatic conformational changes in the 
protein. The events create a large transmembrane β-barrel that perforates the membrane 
[Tilley et al., 2005]. 
 
 
 
Fig. 4: Protein configuration of pneumolysin monomer.  
Structure fitted to perfringolysin O. PLY consists of four 
domains. Domain 4 binds membrane cholesterol with high 
affinity. Domain 1 and 2 are responsible for oligomerization and 
domain 3 penetrates the membrane by unfolding of the 
transmembrane hairpin regions (TMH) 1 and 2. 
(Source: [Rossjohn et al., 2007]) 
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Pneumolysin is a four-domain protein. Its structure has not yet been solved in detail, but was 
fitted to the well investigated perfringolysin O (PFO) [Rossjohn et al., 2007], which is also a 
member of the CDCs. Pneumolysin is believed to be released via bacterial autolysis induced by 
the bacterial virulence factor autolysin (Lyt A), during the late log-phase of bacterial growth 
[Berry et al., 1989]. Also the treatment with cell wall degrading antibiotics, such as penicillin, 
can induce release of high amounts of the toxin [Mitchell and Mitchell, 2010]. Upon 
cholesterol-recognition (proper binding requires at least 30 mole % of membrane cholesterol 
[Alving et al., 1979]), monomers of PLY oligomerize on the host cell membrane. 
The membrane recognition motif in domain 4 (D4) is discussed controversially. It was widely 
believed that a highly conserved tryptophan-rich undecapeptide sequence at the base of D4 
mediates cholesterol recognition and binding [Jacobs et al., 1999]. Recent studies, however, 
show that a threonin-leucin pair (at position 459/460 in PLY), that is conserved in all CDCs and 
located in loop 1 of D4, is responsible for membrane binding of the monomers [Farrand et al., 
2010]. Oligomerization and penetration involves domains 1-3 (D123), with D3 dipping through 
the membrane and thus destroying membrane integrity.  
 
 
 
Fig. 5: Pore-formation mechanism. 
Toxin monomers bind to cholesterol on the PM 
and oligomerize (II). This leads to a 
conformational change, which induces the 
penetration of the membrane by unfolding of 
domain 3 of each monomer (III). (Source: 
[Heuck et al., 2010], modified) 
 
 
1.3.3 Role in pathogenicity 
Pneumolysin plays an extraordinary role in the pathogenicity of S. pneumoniae. Lack of the 
toxin lowers induction of pro-inflammatory response and tissue inflammation in general, the 
production of reactive oxygen species and other immune mediators, and thus hampers a 
proper bacterial clearance. Consequently, PLY deficient strains are associated with improved 
survival, lower morbidity and decreased numbers of bacteria in the blood [Canvin et al., 1995; 
Kadioglu et al., 2000].  
The toxin is, as well, the main trigger of immune responses against S. pneumoniae. Toll-like 
receptor 4 (TLR-4) and the TLR adaptor myeloid differentiation factor 88 are known to be 
essential for macrophage expression of Tumor Necrosis Factor-alpha (TNF-α) and Interleukin-6 
(IL-6) in response to PLY [Malley et al., 2003], but also TLR-2 is supposed to play a role in 
bacterial clearance [van Rossum et al., 2005]. 
T-cells represent the main cellular response to pneumococcus, and T-cell depletion also 
reduces bacterial clearance from infection sites [van Rossum et al., 2005]. Furthermore, PLY is 
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a major target for anti-pneumococcal antibodies. HIV-1 infection is accompanied by impaired 
production of anti-PLY antibodies, which explains higher susceptibility to invasive 
pneumococcal disease of HIV patients [Amdahl et al., 1995]. Pregnant women with high 
antibody levels against PLY are less likely to have infants who become colonized with 
S. pneumoniae during their infancy, and antibodies, in general, are thought to be important in 
the clearance of colonization with the bacterium [Dagan et al., 2002]. PLY is additionally a very 
potent activator (but also in-activator) of the classical complement pathway, as it shows 
sequence homology with the acute phase protein, C-reactive protein (CRP), and thus can bind 
to the Fc portion of immunoglobulin and to C1q [Paton et al., 1984]. This leads to an impaired 
opsonic activity of serum PMNLs (polymorphonuclear leukocytes) in vivo, which in turn has a 
strong influence on bacterial clearance [Paton et al., 1984]. 
 
 
 
Table 1: Pathogenicity of S. pneumoniae.  
   [Mitchell and Mitchell, 2010] 
Virulence factor Effect  
polysaccharide capsule  protection from phagocytosis by prevention of binding of 
iC3b (complement system) and Fc (immunoglobulin)  
 enhancement of colonization  
 prevention of mechanical removal by mucus 
 restriction of autolysis 
pneumolysin (PLY) high, lytic concentrations:  
 pore formation and cell lysis/death 
low, sub-lytic concentrations:  
 activation of the classical complement pathway 
 promotion of inflammation 
 production of reactive oxygen intermediates (both 
mediated by interaction with TRL-4) 
 astrocytic process retraction, cortical astroglial 
reorganization, interstitial tissue retention 
 enhanced penetration of bacteria and toxic 
macromolecules [Hupp et al., 2012], and brain damage in 
general 
hyaluronidase  enhancement of spreading and colonization 
neuraminidase A (NanA)  enhancement of colonization 
 biofilm formation 
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pilus  enhancement of binding to epithelial cells 
 stimulation of proinflammatory cytokines 
lipoproteins (PsaA, SirA, PpmA)  adhesion to cells 
 colonization 
autolysin (LytA)  release of PLY from the bacteria 
 release of inflammatory cell wall degradation products 
pneumococcal surface proteins 
(PspA, PspC) 
 interaction with the complement 
 adhesion 
genome variation  evolutionary advantages  
 resistance against antibiotics 
 
 
1.4 The cytoskeleton 
1.4.1 General properties 
Proper functioning of a cell is dependent on its adaptability and motility, its mechanic stability, 
its ability to communicate with its environment and to accurately organize its interior. These 
properties are provided to the cell by the components of its cytoskeleton, which consists of 
three different filament systems, working collectively together. 
The cytoskeleton tears the chromosomes and dividing cells apart during mitosis, it drives 
trafficking of organelles and molecules throughout the cytoplasm, supports the fragile plasma 
membrane and is part of the intercellular connections and mechanical linkages, that help the 
cell to communicate and bear mechanic stresses and tensions, that occur when the 
environment shifts and changes. The cytoskeleton enables cells to crawl across surfaces and 
sperms to swim. It drives axon and dendrite growth, and last, but not least, controls the 
diversity of eukaryotic cell shapes. 
 
 
 
Fig. 6: Schematic of the components of the 
cell cytoskeleton. 
Actin filaments, microtubules and intermediate 
filaments provide mammalian cells numerous 
essential skills, like motility, molecular trafficking 
and stability.  
(Source: [Alberts et al., 2008], modified*) 
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The cytoskeleton is divided into three subgroups, intermediate filaments (e. g. GFAP in 
astrocytes), microtubules, and the microfilaments (actin) (Fig. 6). Intermediate filaments 
provide mechanical strength to the cell. They line the inner face of the nuclear envelope to 
form a protective cage for the DNA. Microtubules position intracellular organelles, and are 
responsible for trafficking, they build the mitotic spindle, and form motile whips called cilia and 
flagella. Microfilaments, fibers composed of actin, are mainly positioned below the plasma 
membrane (building the actin cortex), thus protecting the lipid bilayer from mechanic harm 
and enabling movement of the whole cell by formation of large actin aggregations that push 
the membrane forward. The filaments are flexible and can easily be bent. They can be 
organized into 2-dimensional networks or 3-dimensional gels. 
If those dynamic aggregations are consisting of parallel actin bundles, they build membrane 
spikes, which are called filopodia. Mesh-like aggregations built from branched actin filaments 
are called lamellipodia. Long actin bundles, reaching from one to the other side of the cell 
comprise stressfibers, often established when tensions are affecting the cell, and under 
conditions of active movement. 
 
 
  
Fig. 7: Actin treadmilling and nucleation. 
A. Treadmilling. In the absence of actin effectors subunits undergo a net assembly at the plus end and 
a net disassembly at the minus end at an identical rate. The polymer maintains a constant length, even 
though there is a net flux of subunits through the polymers (dark red). 
B. Nucleation. Two actin monomers bind relatively weakly to each other, but addition of a third 
monomer makes the group more stable. Further monomer addition leads to the formation of a stable 
“nucleus”.  
C. Kinetics. The formation of a nucleus is very slow (explains the lag phase seen during actin assembly). 
The lag phase is followed by rapid actin polymerization, resulting in an equilibrium phase. ([Alberts et al., 
2008], modified*) 
C 
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As already mentioned, the cytoskeletal systems are no static structures, but very dynamic and 
adaptable. They can either persist for a longer time, or change spontaneously, according to 
need. Alberts et al. use a very suitable example, comparing the cytoskeleton to an ant trail, 
extending from an ant nest to a selected picnic site. Such trail can persist for many hours, but 
can also be rearranged spontaneously, if a better picnic site is discovered. Like the single 
molecules that compose the cytoskeletal structures, every single ant will be concerted into a 
new trail. 
Intermediate filaments are ropelike structures of about 10 nm diameter, composed of 
intermediate filament proteins, a large and heterogeneous family of proteins. 
Microtubules (MTs), which are hollow cylinders, are made of the protein tubulin, and have an 
outer diameter of 25 nm. One microtubule end is usually attached to a MT-organizing center 
(MTOC), called a centrosome [Alberts et al., 2008]. 
 
 
1.4.2 Actin - treadmilling - nucleation 
Actin microfilaments are composed of actin protein subunits, aggregated into two-stranded 
helical polymers with a diameter of 5-9 nm. Of the three isoforms of actin, only the β- and the 
γ-form are part of cytoskeletal structures. The α-isoform is part of muscle tissue and the 
contractile apparatus. Actin subunits are globular polypeptide chains with an ATP (Adenosine 
triphosphate) nucleotide binding site. They assemble in a head-to-tail manner to generate 
filaments with a distinct structural polarity. Two actin protofilaments twist around each other in 
a right-handed helix to form one actin filament (Fig. 8). This determines two possible forms of 
actin, G-actin (monomeric) and F-actin (filamentous).  
 
 
 
 
 
Fig. 8: Actin monomer and actin filament. 
In the actin monomer ATP/ADP is bound in a 
deep cleft in the center. Each monomer has a 
certain orientation. The arrangement of 
monomers leads to the formation of 
protofilaments. Two of those wind around each 
other to form an actin microfilament, with a 
twist repeating every 37 nm. (Source: [Alberts 
et al., 2008], modified*) 
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The orientation of the monomers within the chain gives the filament a structural polarity, 
where the kinetic rate constants for association and dissociation are often much greater at one 
end than at the other. The more dynamic end of a filament, where both growth and shrinkage 
are fast, is called the plus end (also barbed end), and the other end is called minus end (also 
pointed end). The ATP-binding cleft on the actin monomer points to the minus end. Actin 
subunits have an enzymatic phosphatase activity, releasing phosphate groups from the ATPs. 
The hydrolysis proceeds very slowly for the monomers, but the process is accelerated as soon 
as a subunit is incorporated into a polymer. The free phosphate (Pi) is released, but the 
nucleotide diphosphate (ADP) remains trapped in the filament structure. 
Thus two different types of filament structures exist, one with ATP bound and one with ADP 
bound. When a nucleotide is hydrolyzed, much of the free energy is stored in the polymer 
lattice.  
If the rate for subunit addition is high (that is if the filament is rapidly growing), then it is 
likely that a new subunit will add on to the polymer before the nucleotide in the previously 
added subunit has been hydrolyzed, so that the tip of the polymer remains in the ATP-bound 
form (ATP cap). 
The rate of subunit addition at the end of a filament is the product of the free subunit 
concentration and the rate constant kon. The kon is much faster for the plus end of a filament 
than for the minus end because of a structural difference between the two ends. The ADP-
bound form leans more readily toward disassembly, while the ATP-bound form leans more 
readily toward assembly. If the concentration of free subunits in solution is in an intermediate 
range, the filament adds subunits at the plus end, and simultaneously loses subunits from the 
minus end. This leads to the phenomenon of treadmilling. Under conditions of “steady-state 
treadmilling”, when addition and dissociation are in balance, the total length of the filament 
remains unchanged. During treadmilling, subunits are recruited at the plus end of the polymer 
in the ATP-bound form and shed from the minus end in the ADP-bound form.  
The ATP hydrolysis that occurs along the way gives rise to the difference in the free energy of 
the association/dissociation reaction at the plus and minus ends of the actin filament and 
thereby makes treadmilling possible.  
The binding of two actin molecules is a relatively weak connection. But as soon as a third actin 
monomer is added to form a trimer, the entire group becomes more stable. Further monomer 
addition can take place onto this trimer, which then acts as a nucleus for polymerization. This 
phenomenon is called nucleation. The assembly of a nucleus is relatively slow, which explains 
the lag phase seen during polymerization of actin. During the growth phase monomers are 
added to the exposed ends of the growing filament, causing elongation. The equilibrium phase 
(steady state) is reached when the growth of the polymer precisely balances the shrinkage of 
the polymer (Fig. 7 C). 
The rapid interconversion between a growing and shrinking stat, at a uniform subunit 
concentration, is called dynamic instability. The change from growth to rapid shrinkage is 
called a catastrophe, while the change to growth is called a rescue. Both dynamic instability 
and treadmilling allow a cell to maintain the same overall filament content, while individual 
subunits constantly recycle between the filaments and the cytosol. Actin filament turnover is a 
typically rapid process, with filaments persisting for only few tens of seconds or minutes. The 
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single subunits themselves are small and can diffuse very rapidly. They can cross the diameter 
of a typical eukaryotic cell in several seconds [Alberts et al., 2008]. 
 
 
1.4.3 The actin cortex and active cell movement 
The actin cortex is located directly below the plasma membrane of animal cells and comprises 
an aggregation of actin and actin binding proteins (ABPs) in a high density. It enables the cell 
to displace actively. Actin polymerization at the leading edge forms a lamellipodium, and its 
firm attachment to the substratum moves the edge forward and stretches the actin cortex. 
Contraction at the rear of the cell pushes the body of the cell forward to relax some of the 
tension. New focal points develop at the front and old ones are disassembled at the rear. 
Repetition of the cycle moves the cell forward in a stepwise fashion. Tight coordination of all 
steps leads to a smooth movement [Alberts et al., 2008]. 
As a place of massive actin accumulation the actin cortex also harbors a high number of actin 
regulator proteins, such as the Arp2/3 complex and Gelsolin (see below). 
 
 
 
Fig. 9: Active movement of animal cells mediated by 
the actin cortex. 
The actin cortex (orange) comprises the massive actin 
aggregation right below the PM. Protrusion of a cell is 
dependent on actin-polymerization at the leading edge of 
the cell, resulting in the formation of a lamellipodium, which 
firmly attaches to the extra cellular matrix. Contraction at 
the rear of the cell pushes the cell body forward to relax 
some of the tension (traction). At the front new focal 
adhesions (FAs) are established, and old ones disassembled 
at the back. Tight coordination of those steps move a cell 
forward in a smooth manner. The newly established cortical 
actin is shown in red. (Source: [Alberts et al., 2008]*) 
 
 
1.4.4 Actin binding proteins (ABPs) 
In vivo actin filaments, microtubules and also intermediate filaments are much more dynamic 
than in vitro. Reason for this is that for each filament system of the cytoskeleton exists a huge 
set of proteins controlling their turnover and structure. These so-called accessory proteins bind 
either to the filaments or their free subunits. Overall, nucleation of monomers is the major 
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step of cytoskeletal filament establishment. Actin nucleation occurs mainly at or near the 
plasma membrane, where the actin cortex is located. From this point also surface protrusions, 
like filopodia and lamellipodia, emerge (indicated in Fig. 12). Although nucleation is the 
initializing and most important step, there are many other cytoskeleton-related reactions to be 
taken care of, when external signals, that arise from changes in the cell environment, hit the 
cell surface and have to be processed inside the cell to remodel the cytoskeleton and trigger a 
reaction of the cell [Alberts et al., 2008]. In the following paragraph the most common of the 
numerous actin binding proteins will be characterized. 
 
 
1.4.4.1 The actin-related protein complex (Arp2/3) 
 
Fig. 10: The Arp2/3 complex. 
The actin related proteins build a heptameric complex that assembles to potently nucleate 
actin polymerization, both de novo, and originating from pre-formed actin filaments at a 
70° angle, which leads to an actin meshwork, mostly seen at the leading edge of protruding 
cells. 
(Source:  Manual of Cellular and Molecular Function, The National University of Singapore, 
2009; Illustrators: Pham Thi Phuong Thao & Theng Tze Yin Meryl (modified); 2011) 
 
 
Nucleation of actin can be catalyzed by two different APBs, the formins and the ARP (actin-
related protein) complex. The Arp complex (also known as Arp2/3 complex) is a seven-protein 
complex, including two actin-related proteins, the ARPs (2 and 3), each of which is about 45% 
identical to actin. The five additional subunits of the complex are p41-Arc, p34-Arc, p21-Arc, 
p20-Arc and p16-Arc.  
The ARPs nucleate actin filament growth from the minus end by capping this side, allowing 
rapid elongation at the other side. Arp can also attach to the side of another actin filament 
while remaining bound to the minus end of the filament that it has nucleated, thereby 
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establishing a branched web. The ARP complex is localized in regions of rapid actin growth, 
such as filopodia and lamellipodia. Signaling molecules and effectors at the cytosolic face of 
the plasma membrane regulate its activity. In vivo and especially in vitro the Arp complex 
requires activation by binding of the conserved C-terminal verprolin-homology-cofilin-
homology-acidic (VCA) domain of an N-WASP (Neuronal Wiskott-Aldrich-Syndrome protein) 
family protein to one subunit of the Arp complex [Alberts et al., 2008; Condeelis, 2001; Mullins 
et al., 1998]. N-WASP possesses several domains, interacting with different factors: a 
pleckstrin homology (PH) domain that binds phosphatidylinositol(4,5)bisphosphate (PIP2), a 
Cdc42-binding domain (GDB) domain, a proline-rich region, a G-actin-binding verprolin 
homology (V) domain, a domain (C) with homology to the actin-depolymerizing protein cofilin, 
and a C-terminal acidic segment (A) [Rohatgi et al., 1999]. 
 
 
1.4.4.2 Gelsolin 
Actin filament severing (a process contrary to nucleation) is processed by the gelsolin 
superfamily of actin binding proteins, whose severing activity is activated by high levels of 
cytosolic Ca2+ [Alberts et al., 2008]. It is one of the most potent actin filament severing 
proteins known. Gelsolin binds to one side of an actin filament, and severs the filament after 
kinking [McGough et al., 1998]. After the severing it stays attached to the barbed end as a 
cap. This results in short filaments, which can neither re-anneal nor elongate their plus ends. 
This in turn leads to a disassembly of the microfilament system. However, gelsolin can also 
have a filament constructive effect, as it increases the number of filaments. In case of an 
uncapping event, the high number of previously generated short filaments, comprises a high 
number of new nucleation sites or polymerization-competent ends, from which actin can grow 
and rebuild the microfilament system [Sun et al., 1999]. It is known that gelsolin is a 
downstream effector of the small GTPase Rac, with calcium ions and phosphoinositides as 
intermediate regulators [Hartwig et al., 1995].  
 
 
1.5 How bacterial toxins intervene with cellular functions 
1.5.1 Toxin strategies 
As mentioned above, bacterial effectors have evolved to alter cell function for their own 
advantage. In this context bacterial toxins have achieved special importance, as being 
released as soluble protein monomers or compounds, they have free access to cell 
membranes, receptors, cell signaling, or even intracellular molecules or structures, in case 
they are translocated to the cytosol via, for example, a type-III secretion system (TTSS) or 
endocytosis. Generally spoken, bacterial effectors can influence the fate of their host cells, 
favoring either death or survival, depending on their needs [Fiorentini et al., 2003]. 
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Mechanisms that lead to the collapse of cells are either induction of necrosis/apoptosis or 
direct and fast destruction of membranous structures and thus initiation of cell lysis. Latter is 
the major approach of pore-forming toxins, like the CDCs (introduced in paragraph 1.3). Via 
formation of big ring-like structures on the membrane and penetration through the lipid-
bilayer they form holes that are big enough (~ 260 Å, 26 nm) to kill the cell. Other toxins 
follow different strategies to alter cell function without cellular destruction. A major target in 
this context is the cell cytoskeleton, especially the actin cytoskeleton, which plays a pivotal 
role in cell stability, cell motility, in intracellular vesicle transport, phagocytosis, and mitosis 
(see paragraph 1.4). Toxins approach the actin scaffold either directly, or they hijack its 
endogenous effector proteins, as described below. 
Invasive toxins of Salmonella (SipA and SipC) interact directly with actin molecules, leading to 
filament bundling and nucleation (SipC), or in case of SipA to a polymerization and 
stabilization of F-actin filaments via reduction of the critical concentration for filament 
formation. Furthermore, SipA functions as a potentiator of SipC, leading to stronger nucleation 
and F-actin bundling [Hayward and Koronakis, 1999; Lilic et al., 2003; McGhie et al., 2001]. 
ADP-ribosylation of actin, which is, for example, carried out by the Clostridium botulinum C2 
toxin and other binary toxins, leads to depolymerization of actin and inhibits its 
polymerization. G-actin, which is ADP-ribosylated at Arg177, cannot polymerize, but it can still 
bind to and cap the barbed ends of pre-existing actin filaments. Thus, further growth of 
filaments from these ends is inhibited, leading to destruction of the actin cytoskeleton. This 
event in turn leads to release of growing microtubules at the cell membrane. Thus, long 
protrusions extending from the cell membrane, develop, which in turn facilitate adherence and 
colonization of the bacteria [Aktories et al., 1986; Schwan et al., 2009]. 
A third mechanism that leads to direct actin modification, namely actin nucleation, is carried 
out by the Tir toxin of Escherichia coli, ActA of Listeria spp., and IcsA of Shigella flexneri. In 
this form of actin nucleation, however, a third component, actin effector proteins like α-actinin 
or Arp2/3 are involved. Function of the Arp complex is explained in chapter 1.4.4.1 of this 
work. It is known that actin pedestal formation of enteropathogenic E. coli is mediated via 
recruitment and activation of Arp complex and WASP (Wiskott-Aldrich syndrome proteins) by 
the Tir toxin [Kalman et al., 1999]. 
Bacterial effectors that do not directly interact with actin, act on its regulators, the so called 
Rho proteins or Rho family of small GTPases. 
 
 
1.5.2 Small GTPases 
Small GTPases (20 to 30kD GTP-binding proteins), which comprise eukaryotic molecular 
switches, have become a major target of toxins, as they regulate substantial events, such as 
cell migration and chemotaxis, cell division, neurite and axon outgrowth, regulation of cell 
polarity, phagocytosis and endosome trafficking, but also cancer progression and metastasis 
(reviewed in [Heasman and Ridley, 2008]). 
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Approximately 1% of the human genome encodes proteins that either regulate or are 
regulated by direct interaction with members of the Rho family GTPases, which is a distinct 
family within the superfamily of Ras-related small GTPases. Members of the Rho (Ras 
homology) family of small GTPases (which comprise at least 20 distinct proteins) function as 
regulators of the cell cytoskeleton (for further review see [Jaffe and Hall, 2005]). Best-
characterized in this group are Rho, Rac and Cdc42. 
Rho was shown to be responsible for the assembly of contractile actin and myosin filaments 
(stress fibers) [Ridley and Hall, 1992], whereas Rac induces cell surface protrusions at the 
leading edge of a cell via enrichment of actin structures below the protruding membrane 
(lamellipodia) [Ridley et al., 1992]. 
 
 
 
Fig. 11: Molecular mechanism of small GTPase activation and deactivation. 
The transition of small GTPases (“Rho”) from an inactive into an active form is 
mediated by GEFs (guanine nucleotide exchange factors) and GAPs (GTPase 
activating proteins). GEFs activate GTPases by promoting the release of GDP and 
the binding of GTP, which in turn induces interaction with their downstream 
effectors. GAPs inactivate Rho GTPases by increasing the intrinsic GTPase activity 
of Rho proteins. Guanine nucleotide-dissociation inhibitors (GDIs) bind to Rho 
proteins, sequestering them in the cytoplasm away from their regulators and 
targets. (Source:[Aktories and Barbieri, 2005]) 
 
 
Cdc42 is known to induce the formation of finger-like actin-membrane structures, which are 
called filopodia [Nobes and Hall, 1995]. The Rho switch is very tightly regulated. The human 
genome contains more than 60 activators (GEFs: guanine nucleotide exchange factors) and 
more than 70 inactivators (GAPs: GTPase activating proteins). Over 60 proteins were identified 
to be targets of the Rho family GTPases (reviewed in [Etienne-Manneville and Hall, 2002]). 
The control mechanism by which those molecular switches function to regulate complex 
cellular signaling events is based on one of the most abundant biochemical strategies, namely 
the cleavage of energetic phosphate-bonds. During the GTP (guanosine tri-phosphate) bound 
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state, the GTPases recognize their target molecules and bind those (on-state), until the 
hydrolysis of GTP to GDP (guanosine di-phosphate) turns them to the off-state and leads to 
the release of target proteins. In this context GEFs promote exchange of nucleotides and thus 
activation, whereas GAPs stimulate the formation into the inactive form via hydrolysis of 
nucleotides. 
 
 
 
Fig. 12: Mechanism of actin 
modification by Rac and 
Cdc42. 
a. Actin structures built up at the 
leading edge of the cell. Within 
the lamellipodia the Arp complex 
and other actin effectors lead to 
the formation of an actin mesh 
(branched actin structures). Out 
of the lamellipodia emanate so 
called filopodia, which contain 
parallel bundles of actin. 
b. Upon activation by their effector proteins (GEFs), small GTPases activate downstream effector proteins 
like WASP and Arp, or, e. g., proteins of the kinase family like the LIM kinase. Those proteins in turn 
influence the actin turnover and lead to actin cytoskeleton remodeling. 
(Source: [Heasman and Ridley, 2008], modified) 
 
 
A third group of GTPase effector molecules are the GDIs (guanine nucleotide dissociation 
inhibitors), of which exist at least four different. GDIs bind inactivated GTPases in the cytosol, 
and consequently prevent translocation to the membrane and thus activation.  
The switch function is based on an interposition of the Rho protein between upstream and 
downstream effectors or signals. An upstream signal stimulates the dissociation of GDP from 
the inactive form, which is followed by the binding of GTP, leading to a conformational change 
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of the downstream effector-binding region, so that this region gets accessible to downstream 
effector molecules [Takai et al., 2001]. 
 
 
1.5.3 Toxin effects on small GTPases 
As small GTPases are of major importance for cell behavior, it is obvious that bacteria have 
evolved mechanisms to intervene with proper function of those. Hijacking of small GTPases by 
bacterial toxins is carried out on two different modes of action. Bacterial effectors either 
directly mimic small GTPase molecules, or act as their activators or inactivators (GEFs or 
GAPs), leading to disturbance of normally regulated nucleotide exchange.  
 
 
 
Table 2: Bacterial toxins targeting Rho GTPases.  
    [Aktories and Barbieri, 2005], modified 
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They also carry out ADP-ribosylation, glucosylation, proteolysis, adenylation, deamidation, or 
tansglutamination reactions on Rho proteins directly [Aktories et al., 1989; Just et al., 1995; 
Masuda et al., 2000; Schmidt et al., 1997; Shao et al., 2002; Yarbrough et al., 2009]. 
Approaching the switch molecules in such dramatic manner allows hijacking and alteration of 
cellular functions. 
 
 
1.6 The brain 
1.6.1 Brain anatomy 
The brain is one of the sterile compartments of the body. Being the center of the nervous 
system and thus the control center of the body, protection demands special effort. Whereas 
the skull protects from mechanic injury, the blood-brain barrier (see below) comprises a 
barrier for all agents that potentially lead to disturbance of brain homeostasis. Further 
protection of the brain and whole nervous system is provided by the meninges, which are a set 
of membranes (Dura mater, Arachnoid mater, Pia mater), enclosing the components of the 
CNS. The subarachnoid space comprises the space between Arachnoid and Pia mater, and is 
filled with cerebrospinal fluid (CSF, liquor), which additionally provides a basic mechanical 
(cushion) and immunological protection to the brain. It occupies also the ventricular system 
around and inside the brain and spinal cord. 
Macroscopically the brain consists of the two symmetric (right and left) hemispheres of the 
cerebrum (forebrain), and the cerebellum (Latin for little brain). The cerebrum is further 
divided into frontal, occipital, parietal, and temporal lobe, each of which harbors different 
neuro-physiological functions. The brain stem is the lower extension that connects with the 
Table 3: Bacterial toxins targeting actin. 
    [Aktories and Barbieri, 2005], modified 
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spinal cord. The Medulla oblongata comprises the lower half of the brain stem. The thalamus is 
located between the cerebral cortex and the midbrain, whereas the Hypothalamus lies below 
the thalamus and synthesizes and secretes several neuro-hormones.  
 
 
 
Fig. 13: Anatomy of the brain. 
The human brain is divided into the right 
and left hemisphere, and the cerebellum. 
The hemispheres are further divided into 
several lobes, each of which has unique 
physiological functions. The hippocampus 
is another paired structure and lies in the 
center of the brain within the Limbic 
System. It is, amongst others, 
responsible for memory and learning. 
(Source: www.clas.ufl.edu/users/nnh 
/sem05/brnpic2-5.htm; 2011) 
 
 
 
The cerebral cortex is a sheet of neurons comprising the outermost part of the cerebrum. It 
consists of up to six horizontal layers, each of which has a different composition in terms of 
neurons and connectivity. The cortex plays a key role in memory, attention, language and 
consciousness. The neurons in this sheet are unmyelinated, and thus appear to be gray (“gray 
matter”). The “white matter” below is formed by myelinated axons, which interconnect 
neurons in different regions of the cortex with each other and with neurons in other parts of 
the CNS.  
Closely associated to the cortex lies the hippocampus (Fig. 13), which is also a paired structure 
with halves in the left and right sides of the brain. It contains two interlocking parts, the 
Ammon‟s horn and the dentate gyrus. The hippocampus is responsible for behavioral 
inhibition, attention, spatial memory, learning and navigation [Kandel, 1996; Squire, 2003]. 
 
 
1.6.2 Neuroglia 
The human brain consists of about 10 billion neurons, however, not being the only component 
of the central nervous system (CNS). The term neuroglia or “nerveglue” was set by Rudolf 
Virchow in 1859, describing the “inactive connective tissue” holding neurons together in the 
CNS. Ramón y Cajal and del Rio-Hortega were later able to distinguish the different supporting 
cell types present in the tissue of the CNS: oligodentrocytes, astrocytes, and microglia. In the 
peripheral nervous system (PNS) the Schwann Cells are the major neuroglial component. 
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Virtually all axons are ensheathed or fenced in by other cells types, providing support or 
trophic supply. 
Astrocytes -which are described in more detail below- comprise the most abundant cell 
population in the brain. They interconnect with each other via gap junctions and with neurons 
and blood vessels through their endfeet, and are responsible for the maintenance of the blood-
brain barrier and brain homeostasis [Sofroniew and Vinters, 2010; Squire, 2003]. 
Oligodendrocytes form with a single sheet of their plasma membrane the myelin sheaths 
around neurons, increasing the rapidity of conduction of nerve impulses along axons by many-
fold.  
Microglia are mediators of immune responses in nerve tissue, and therefore are often 
designated the macrophages of the brain and PNS. Microglia are resident in the healthy brain 
in a ramified phenotype, but can rapidly transform into migratory, ameboid and phagocytic 
forms by receiving an activation signal. They become activated in any kind of 
neurodegenerative condition. In the mouse brain microglia constitute 5-20% of the total cells 
[Squire, 2003]. 
 
 
1.6.3 Astroglia 
1.6.3.1 Astrocytic features 
One major group of supportive cells in the brain are astroglia, also called astrocytes. 
Astrocytes are star shaped, process bearing cells, that constitute from 20 to 50% of the 
volume of most brain areas, outnumbering neurons by a five-fold. There are no regions devoid 
of astrocytes in the CNS, but they virtually tile the nervous system in a non-overlapping 
manner.  
 
Fig. 14: Astroglia. Schematic 
of astrocytes within the 
neuronal network. 
The schematic shows the 
embedding of astrotcytes (green) 
in brain tissue. The cells are 
closely interconnected with 
neurons (dots), and astrocyte-
end feet are tightly applied to the 
walls of capillaries. Microglia 
(black) comprise highly motile 
immune cells, and oligodentro-
cytes (white) ensheath neurons 
with their PM (Source:[Baumann 
and Pham-Dinh, 2001], modified) 
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Although astrocytes can adopt about 11 different phenotypes, the protoplasmic and the fibrous 
forms are the most prominent. They develop from radial glial cells and serve as a scaffold for 
the migration and guidance of neurons during early development of the latter. In the mature 
brain, astrocytes fence in neurons and oligodentrocytes. The single astoglia cells are connected 
to each other via gap junctions, thereby forming a big syncytium throughout the brain, 
allowing ions and small molecules to diffuse across the brain parenchyma.  
There are different distinct attributes that make it easy to identify astrocytes: 
o their star-shaped exterior 
o their end feet on capillaries 
o GFAP: a special sort of intermediate filaments, only present in astrocytes 
o S-100: a calcium binding protein 
o a glutamine sythethase 
o gap junctions consisting of connexin proteins 
o desmosomes 
o glycogen granules 
o membrane orthogonal arrays  
o the Aldh protein [Barres, 2008] 
[Sofroniew and Vinters, 2010; Squire, 2003] 
 
 
1.6.3.2 Astrocyte - neuron interaction 
As already mentioned, there is an intimate relation between neurons and astrocytes, in which 
the neurons are highly dependent on the release of growth factors and re-uptake of 
neurotransmitters by the astrocytes. During neurotransmission, neurotransmitters and ions 
are released into the synaptic cleft in high amounts. Fast and proper cleanup of those 
substances afterwards are of high importance for the recycling and avoidance of interference 
with upcoming synaptic events. One of the major tasks of astrocytes in this context is the re-
uptake of glutamate (besides e. g. GABA and ATP). They convert glutamate into glutamine and 
afterwards pour it into the extracellular space, where it is taken up by neurons. Neurons in 
turn use the glutamine to generate glutamate and γ-aminobutyric acid (GABA), which 
comprise potent excitatory and inhibitory neurotransmitters, respectively. This recycling 
process ensures proper excitability of neurons. 
Uptake of sodium through ion channels and removal via gap junctions over the syncytium 
leads to a so called “spatial buffering”. Additionally to the K+-channels, astrocytes contain 
channels for Na2+, Cl-, HCO3+, and Ca2+. In response to stimuli, calcium waves are generated 
in astrocytes, thought to be mediated by secondary messengers, diffusing along gap junctions. 
Those kind of inter-cellular connections have also been detected between astrocytes and 
neurons, thus being not only participating in astrocyte-astrocyte, but also in astrocyte-neuron 
physiology. 
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Besides the metabo-trophic and structuring functions, astrocytes are known to be integral 
functional elements of the synapses. They respond to neuronal activity and regulate synaptic 
transmission and plasticity. There is a bi-directional communication happening between the 
two cell types, leading to an active involvement of astrocytes in processing, transfer, and 
storage of information by the nervous system (reviewed in [Araque and Navarrete, 2010; 
Squire, 2003]. 
 
 
1.6.3.3 Astrogliosis 
In case of neuronal injury, astrocytes take over an active part in wound closure by formation 
of a glial scar. Reactive astrogliosis is a hallmark of diseased CNS tissue, and is defined as an 
abnormal increase in the number of astrocytes due to the destruction of nearby neurons. It 
occurs in response to all kind of forms and severities of CNS damage and disease, even to 
minimal perturbations, and leads to molecular, cellular and functional changes in astrocytes. 
Depending on the form of insult, the reactive astrocytes undergo changes that range from 
alteration in molecular expression, over hypertrophy to enhanced proliferation and scar 
formation. Astrogliosis is regulated in a context-specific manner by extra- and intracellular 
signaling molecules (reviewed in [Sofroniew, 2009]).  
 
 
1.6.3.4 The blood-brain barrier 
The brain comprises a sterile, well-protected compartment with highly limited access for all 
kinds of agents that could imbalance brain homeostasis. This limitation is guaranteed by the 
blood-brain barrier (BBB), which is formed by brain epithelial cells lining the cerebral 
 
Fig. 15: Co-localization of neurons and 
astrocytes. 
Astrocytes and neurons are tightly associated in 
brain tissue. Astrocytes support neurons 
mechanically and metabo-trophically. Dysfunction of 
astrocytes will result in neuron instability. Scale bar: 
15 µm. 
(neurons: anti-actin/Cy3, red; astrocytes: anti-
GFAP/FITC, green) 
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microvasculature. It protects the brain from fluctuations in plasma composition, which could 
lead to neuronal dysfunction.  
Complex tight junctions between the adjacent endothelial cells force the major part of the 
molecular traffic to take a transcellular route across the BBB, rather than moving paracellularly 
through the junctions, as it happens in most other endothelia. Small molecules as oxygen, 
carbon dioxide or ethanol and lipophilic drugs can diffuse freely through the lipid membrane.  
 
 
 
The traffic of hydrophilic molecules, in contrast, is regulated by specific transport systems on 
the luminal and abluminal membranes. Astrocytic perivascular end feet are of particular 
importance for BBB stability. Astrocytes can upregulate many features of the barrier, leading 
to tighter tight junctions (physical barrier), the expression and polarized localization of 
transporters (transport barrier), and specialized enzyme systems (metabolic barrier). Their 
end feet are closely applied to the microvessel wall and show characteristic features for that 
location, including a high density of orthogonal arrays particles (OAPs) containing the water 
channel aquaporin 4 (AQP4) and the Kir4.1 potassium channel, which are involved in ion and 
volume regulation (reviewed in [Abbott, 2002; Abbott et al., 2006]).  
 
 
1.7 Basics of this study 
Learning and memory are highly dependent on establishment and maintenance of synaptic 
contacts, and the most complex form of these synaptic contacts are located in the cortex. In 
 
Fig. 16: Barrier sites in the CNS. 
(1) BBB: The brain epithelium forms 
the blood-brain barrier, which is 
strongly supported by astrocytes. 
It comprises a highly selective barrier, 
protecting the brain from the entry of 
large hydrophilic molecules such as 
proteins and peptides, hydrophilic drugs 
and especially from the penetration of 
pathogenic agents. 
(2) The arachnoid epithelium forms the 
middle layer of the meninges [Abbott et 
al., 2006]. 
(modified version of [Segal, 1990]) 
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this region the synaptic communication density and complexity is highest. Being positioned in 
an intimate proximity to the meninges and the subarachnoid space, where the pneumococci 
proliferate in the course of bacterial meningitis, and thus being exposed to substantial 
amounts of pneumolysin, the question arises whether the action of the toxin results in synaptic 
changes. Preliminary evidence demonstrates the existence of dendritic spine changes upon 
pneumolysin challenge, meaning it has a direct toxic effect on neuronal cells [Gerber and Nau, 
2010; Iliev et al., 2009]. Furthermore, pneumolysin is known to induce cytotoxicity to 
microvascular epithelial cells of the BBB, which allows the bacteria to easily gain access to the 
brain [Zysk et al., 2001]. Astrocytes, as a part of the BBB, and as an essential brain sub-
population, therefore comprise a main subject of interest when investigating bacterial 
meningitis. It is now known that the reshaping of astrocytes by PLY induces the remodeling of 
the structure of host brain tissue and induces interstitial fluid retention. Those alterations 
improve the penetration of toxic macromolecules and bacteria into the brain tissue [Hupp et 
al., 2012]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*: “Copyright 2008 from Molecular Biology of the Cell by Alberts et al. Reproduced by 
permission of Garland Science/Taylor & Francis Books, LLC.” 
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2 METHODS 
2.1 Pneumolysin preparation 
Pneumolysin (PLY) and all variants of the toxin were friendly provided by Prof. Timothy Mitchell 
(University of Glasgow) as purified proteins in phosphate buffered saline (PBS). PLY was 
prepared as follows. The toxin was expressed in E.coli XL-1 cells and purified by hydrophobic 
interaction chromatography as described in [Mitchell et al., 1989]. The LPS content of purified 
toxin was determined by using the Limulus Amebocyte Lysate Kinetic-QCL Kit. All purified 
proteins had less than 0.6 endotoxin units/μg of protein. The purified wild-type toxin had an 
activity of about 5 x 104 hemolytic units/mg. One hemolytic unit was defined as the minimum 
amount of toxin needed to lyse 90% of 1.5 x 108 human erythrocytes per ml within 1 h at 
37°C. The non-toxic delta6 version of PLY was generated by site-directed mutagenesis. 
Truncated mutants D1-3 (D123; a toxin fragment containing domain 1, 2 and 3), D4 (the 
domain 4 fragment of PLY), and GFP-tagged variants were purified similarly. 
 
 
2.2 Pneumolysin concentration and lytic capacity determination 
Toxin charges in general differ in their cytotoxicity, the capacity to lyse cells, which is 
dependent on the presence of active toxin molecules within the charge. In this work two 
different toxin charges were used, each of which had a different stock concentration and lytic 
capacity, as judged by LDH (lactate dehydrogenase) tests. With the help of propidium iodide 
(PI), the lytic capacity of different PLY concentrations was determined. Propidium iodide binds 
to DNA by intercalating between the bases with little or no sequence preference and with a 
stoichiometry of one dye per 4–5 base pairs of DNA. PI is membrane impermeant and 
generally excluded from viable cells. PI is commonly used for identifying dead cells in a 
population and as a counterstain in multicolor fluorescent techniques. With a size of 668 kDa, 
it has the capacity to cross the membrane of the cells via the pores formed by PLY. 
PI was applied to mock-treated or PLY-treated cells in a dilution of 1 µl per 1 ml, directly into 
the imaged chamber. Subsequently the number of permeabilized cells was determined with the 
help of the ImageJ software. The total number of cells was determined by Hoechst nuclei 
staining. In order to define sub-lytic concentrations of the toxin, amounts between 0.05 and 
0.5 µg/ml were applied to the cells and permeabilization was determined. For the first toxin 
charge, 0.1 µg/ml of PLY were assigned to be sub-lytic. As the second PLY charge was found to 
contain less active toxin molecules, the concentration had to be adapted in order to be 
equivalently toxic as the first charge. Thus, 0.2 µg/ml of PLY were used for the following 
experiments. 
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2.3 Labeling of PLY with Atto488 
PLY-Atto488 was labeled and provided by Christina Förtsch, University of Würzburg. 
Atto488 as NHS-Ester was added to PLY in a 4-fold molar excess (in 0.1 M bicine buffer, pH 9). 
Alkaline conditions were maintained during the labeling reaction for 30 min at room 
temperature in the dark. The labeling reaction was terminated by adding Tris-Cl (final 
concentration 10 mM, pH 8.0). The excess dye was removed by using a gel-filtration column. 
Covalent bonding was verified by an SDS-PAGE of the eluted fractions and examination on an 
UV-transilluminator. Concentration of labeled toxin was calculated after protein determination 
with BCATM Protein Assay Kit. Detailed analysis of membrane binding, lytic capacity and 
labeling confirmed that the labeled toxin behaved identically with the wild-type PLY. 
 
 
2.4 Preparation of cells 
All preparation steps were carried out under a binocular with an external light source, and in 
ice-cold PBS (1x) for optimal conservation of tissue. Primary astrocytes were prepared from 
cortices of C57 BL/6 mice (postnatal day 3), or Sprague Dawley rats (postnatal day 3-5) as 
mixed cultures with microglia.  
The handling of animals was performed according to the regulations of the German Animal 
Protection Law with approval from the Government of Lower Franconia, Bavaria, Germany.  
After decapitation of the newborn rodents, the brain was prepared out of the skull by opening 
of the skullcap. The brain meninges and the cerebellum were removed, and the remaining 
parts were homogenized, washed and seeded in 75 cm2 cell culture flasks in Dulbecco‟s 
Modified Eagle Medium (D-MEM) with high glutamate content. The growth medium was 
complemented with 10% fetal calf serum (FCS) and 1% penicillin/streptomycin. The culture 
flasks were coated with poly-L-ornithine (PLO). The cultures were kept at 37°C and 5% CO2 for 
at least 14 days, until the astrocytes/microglia co-culture had properly differentiated, and 
other cell types had been abolished. 
For biochemical approaches the microglia fraction of the mixed cultures was reduced by 
rigorous agitation of the culture flask (400 rpm) for at least 4 hours at 37°C on an orbital 
shaker. The medium, containing the detached microglia, was removed subsequently. 
 
 
2.5 Cell treatment 
For the use in experiments, the astrocytes were reseeded in glass-bottom chamberslides (for 
immunocytochemistry), chambered cover-glass bottom slides (for live cell imaging) or culture 
dishes (for biochemical assays), which were coated with poly-L-ornithine (PLO).
 
The cells were treated in serum-free D-MEM GlutaMax or in Leibovitz‟s imaging medium. 
Wildtype-pneumolysin (WT-PLY) was used in concentrations of 0.1-0.5 µg/ml. All experiments 
were carried out temperate at 37°C. Control cells (mock) were treated with an appropriate 
amount of pure medium. 
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In order to distinguish living cells from permeabilized cells, propidium iodide (PI) was added to 
the cells right before imaging in a 1:1000 dilution in the imaging medium or buffer. PI is able 
to enter cells as soon as their membrane becomes permeabilized. It emits fluorescence at 
around 560 nm. The total amount of cells in one imaging field was determined by adding 
Hoechst stain in a dilution of 1:1000 to the imaging medium or buffer at the end of an 
experiment. Hoechst stains the nuclei of living cells, and is excited by ultraviolet light. 
Bioactive compounds were applied as follows: 
Cytochalasin D: 4 µM 
NSC23677 Rac1 inhibitor: 10 µM 
C3bot exoenzyme RhoA inhibitor (ADP-ribosyltransferase): 0.1 µg/ml 
Pretreatment with those components was carried out for 1 hour at 37°C. 
 
 
2.6 Immunocytochemistry 
Cells were re-seeded in glass-bottom cultureslides, which were coated with PLO. After 
treatment, the cells were washed in 1x PBS and fixed in 4% paraformaldehyde (PFA) in PBS 
for 30 minutes at room temperature (RT). Subsequently the cell membranes were 
permeabilized with 0.1% TritonX-100 for 10 minutes at RT, and unspecific binding-sites were 
blocked with 4% BSA in PBS for 30 minutes, also at RT. Primary antibodies were applied in 
concentrations, according to manufacturer recommendations, for 1 hour at RT. Goat anti-
mouse or anti-rabbit Fab fragments, labeled with FITC or Cy3 were used to visualize the 
primary antibodies. Secondary antibodies were diluted 1:200 to 1:500 in 1x PBS and applied 
for 1 hour at RT. 
 
 
2.7 Transfection of cells 
For transfection of astrocytes the MagnetofectionTM approach was used following manufacturer 
instructions. MagnetofectionTM is a suitable method to transfect cells in culture. It is based on 
an association of vectors with magnetic particles, which, by magnetic force, are driven 
towards, or even into the target cells. The magnetic nanoparticles are coated with cationic 
molecules. Their association with the gene vectors (DNA, siRNA, ODN, virus, etc.) is achieved 
by salt-induced colloidal aggregation and electrostatic interaction. With the help of the 
magnetic plate, the beads are targeted to the cell membrane, and thus endocytosed by the 
cells. 
1 µg plasmid DNA was mixed with 1 µl/µl pDNA of magnetic beads and incubated in 100 µl D-
MEM (w/o FCS and antibiotics) at room temperature for 20 minutes. The mixture was 
supplemented with a suitable amount of medium, and applied to the cells in fresh growth 
medium and the culture slide was positioned on a magnetic plate for 15 minutes. The cells 
were incubated at 37°C over night. 
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Plasmids used for transfection: 
pTagRFP-actin 
pLifeAct-TagRPF (see p. 44) 
 
Fig. 17: MagnetofectionTM 
(schematic). 
The method associates nucleic acids 
with magnetic nanoparticles, which are 
coated with cationic molecules. The 
magnetic plate targets the beads 
towards the cell membrane and induces 
endocytosis by the cells. 
 
 
2.8 Baculovirus transduction 
To visualize the plasma membrane or the actin cytoskeleton of the astrocytes the Molecular 
Probes CelluarLightsTM Baculovirus vector transfer system was used, also according to 
manufacturer instructions. The virus enters mammalian cells and directs the expression of 
auto-fluorescent proteins that are localized to specific subcellular compartments and organelles 
via signal peptide or protein fusion. 
The virus suspension was applied in a ratio of 1:5 in Ca2+- and Mg2+-free D-PBS (CellularLights 
suspension 1 part, D-PBS 5 parts) and the cells were incubated with the mixture at 37°C for 
4 hours with gentle agitation. Afterwards an enhancer solution was added to the cells and the 
mixture was incubated for additional 2 hours at 37°C. The solution was exchanged to growth 
medium and the cells were further incubated at 37°C over night. 
 
Fig. 18: Baculovirus transduction with 
Organelle LightsTM (schematic). 
Organelle Lights™ reagent delivery is 
mediated by an insect virus (baculovirus) that 
is noninfectious to mammalian cells. 
Organelle Lights™ reagents express 
fluorescent protein–signal peptide fusions for 
accurate and specific targeting to subcellular 
compartments and structures, such as the 
plasma membrane or actin. 
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2.9 Microscopy 
2.9.1 Bright field microscopy 
Bright field microscopy is the simplest form of microscopy. Samples are illuminated with white 
light from below, and observed from above. This type of microscopy was used to determine 
sound conditions of cell cultures, also for live cell imaging, and in biochemical approaches to 
determine the establishment of GUVs (described below). Cell preparation was also carried out 
under a bright field binocular. 
 
 
2.9.2 Fluorescent microscopy 
Fluorescent microscopy is an essential and helpful tool in biology and biomedical science. 
Fluorescence is defined as the absorption and subsequent re-radiation of light by organic and 
inorganic specimens. The emission of light happens nearly simultaneously with the absorption 
of the excitation light. Therefore this form of microscopy is very suitable to investigate probes 
of biological origin. Through the use of multiple fluorescence labeling, different probes can 
identify several target molecules simultaneously. For this purpose so called fluorophores are 
used, which are excited by specific wavelengths of irradiating light and emit light of defined 
and useful intensity. Fluorescent microscopy was applied for fixed samples 
(immunocytochemistry), but also for time lapse imaging, imaging of fluorescently tagged 
actin, and for all approaches carried out on the confocal microscopes (see below). 
 
 
2.9.3 Live cell imaging / time lapse imaging 
Live cell experiments were carried out on a temperate Olympus Cell^M imaging fluorescent 
system, using a 20x dry objective or a 60x oil immersion objective. For live imaging purpose 
the cells were kept in Leibovitz‟s imaging medium, without phenol red at constant pH. 
Snapshots were taken at different time intervals, ranging from 5 seconds to about 2 minutes, 
depending on the experiment, in order to create a sequence of stacks. 
 
 
2.9.4 Confocal microscopy 
Confocal imaging is used for observation of either fixed, or living cells and tissues that are 
labeled with one or more fluorescent probes. Thick specimens, as well as cells can be easily 
investigated in depth by collection of serial optical sections (z-stacks). Other advantages over 
conventional optical microscopy are the shallow depth of field and the elimination of out-of-
focus-glare. The optical detection limit of confocal microscopy is determined by the diffraction 
limit of light (200-300 nm). The illumination of the sample is achieved by scanning one or 
more focused beams of light, usually from a laser, across the specimen. 
METHODS 
35 
 
High-resolution time lapse imaging was performed on a Leica LSM SP5 using a 512x64 pixel 
frame, z-stacking with 10 layers and sequential scan. This kind of microscope was also used 
for documentation of fixed samples and for imaging of GUVs (see below). 
 
(Based on Nikon MicroscopyU by Kenneth R. Spring and Michael W. Davidson). 
 
 
2.10 Protein Biochemistry 
2.10.1  Small GTPase activation pull down assays 
Pull down assays were carried out following manufacturer instructions. In order to prevent 
previous GTPase activation by components of the culture medium (components of the FCS), 
the cells were starved over night in serum-free medium (D-MEM). After treatment with PLY in 
the starving medium for the appropriate time (5, 15, 30 minutes), the suspension was 
aspirated and the cells were washed once with cold 1x PBS. After aspiration of the PBS, the 
cells were lysed with 1 ml cell lysis buffer (50 mM Tris, pH 7.5, 10 mM MgCl2, 0.5 M CaCl, 2% 
Igepal). The lysate was centrifuged to remove membrane fractions and the supernatant was 
applied to PAK-PBD for Rac1 and to Rhotekin agarose beads for RhoA, respectively. The lysate-
beads suspension was rotated at 4°C for one hour, then centrifuged. The supernatant 
comprised the fraction, containing inactive GTPases. The beads pellet, containing the activated 
GTPase fraction, was washed with wash buffer (25 mM Tris, pH 7.5, 30 mM MgCl2, 40 mM 
NaCl) for 3 times. To both fractions SDS sample buffer (containing 2.5% β-mercaptoethanol) 
was added (1x end concentration of the buffer), and the samples were boiled at 99°C for 3 
minutes. 
The pulled down activated GTPase proteins were electrophoresed on SDS-PAGE gradient gels 
(4-12% Bis-Tris). The separated proteins were transferred to a PVDF Imobilion-P transfer 
membrane via semi-dry blotting. Unspecific binding sites on the proteins were blocked using 3-
5% non-fat milk in PBS-T (0.1%) and RhoA and Rac were tagged with the corresponding 
antibodies. After incubation with specific horseradish peroxidase-conjugated secondary 
antibodies, the tagged proteins were detected using ECL Plus Western Blotting reagent and a 
Fluorchem Q machine. Blots were evaluated via densitometric analysis of bands. In the 
evaluation of the GTPase activation assays, the amount of activated GTPases was equalized to 
total amount of GTPases in the cell lysate. 
 
 
2.10.2  Cytoskeleton Isolation Assays 
Primary astrocytes were seeded to 60 mm or 100 mm dishes, coated with PLO, and grown to a 
dense cell monolayer in culture medium (D-MEM, 10% FCS, 1% Pen/Strep). After changing 
the medium to pure D-MEM, the cells were challenged with 0.2 µg/ml of toxin for 10 minutes. 
The cells were washed with cold PBS and subsequently harvested with the help of a cell 
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scraper in cell lysis/cytoskeleton stabilization buffer (50 mM PIPES, pH 6.9, 5 mM MgCl2, 5 mM 
EGTA, 20% v/v Glycerol, 0.2% v/v Nonidet P40, 0.2% v/v Triton X-100, 0.2% v/v Tween 20, 
0.01% 2-mercapto-ethanol, 0.001% Antifoam C; pre-warmed to 37°C). In order to achieve 
complete lysis, the cells were further homogenized with a 27G syringe. When performing 
microtubule reducing experiments, 1/100th volume of nocodazole was added. For F-actin 
reduction 1/200th volume of gelsolin and 1/100th volume of cytochalasin D were added. For 
degradation of both cytoskeleton components, all three agents were added. The samples were 
incubated at 37°C for 30 minutes, and subsequently ultracentrifuged at 50.000 x g for 1 hour 
at 37°C. The supernatants were kept on ice after centrifugation. The pellet fractions were 
resuspended in ice cold MilliQ water for 1 hour, for complete dissociation of cytoskeleton 
components. 10 µM CytoD were added for acceleration of the process. The samples were 
diluted in SDS-sample buffer (containing 2.5% β-mercaptoethanol), boiled at 99°C for 3 
minutes, and electrophoresed on SDS-PAGE gradient gels (4-12% Bis-Tris). The separated 
proteins were transferred to PVDF Imobilion-P transfer membranes via semi-dry blotting. 
Unspecific binding sites on the proteins were blocked using 3-5% non-fat milk in PBS-T (0.1%) 
and PLY was tagged with a specific PLY antibody. After incubation with a specific horseradish 
peroxidase-conjugated secondary antibody, the probed PLY was detected using ECL Plus 
Western Blotting reagent and a Fluorchem Q machine.  
 
 
2.10.3  Preparation of G-actin and F-actin 
In order to obtain G-actin, non-muscle actin, isolated from human platelets (>99% pure), was 
reconstituted in a buffer containing 5 mM Tris-HCl, pH 8.0, 0.2 mM CaCl2, 0.2 mM ATP, 5% 
(w/v) sucrose, and 1% (w/v) dextran. In order to obtain F-actin, 1/10 actin polymerization 
buffer (500 mM KCl, 20 mM MgCl2, 10 mM ATP) was added to the G-actin, and the solution 
was incubated at 24°C for 1 hour. Preformed F-actin was reconstituted in a general actin 
buffer (5 mM Tris-HCl pH 8.0, 0.2 mM CaCl2). 
 
 
2.10.4  Actin binding assays 
Freshly prepared F-actin (see above) (4.6 μM) together with PLY and its variants (2.5 μM) was 
incubated for 1 hour at 24°C at a total volume of 100 μl, subsequently centrifuged at 
150,000 x g. The pellet, containing the actin was resuspended in 50 μl MilliQ water. SDS 
sample buffer (containing 2.5 b β-mercaptoethanol) was added to both fractions and the 
samples were boiled at 99°C for 3 minutes, and subsequently electrophoresed on SDS-PAGE 
gradient gels (4-12% Bis-Tris). The gels were either directly stained with Coomassie blue 
protein stain, or the separated proteins were transferred to PVDF Imobilion-P transfer 
membranes via semi-dry blotting. Unspecific binding sites on the proteins were blocked using 
3-5% non-fat milk in PBS-T (0.1%) and PLY was tagged with a specific PLY antibody. After 
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incubation with a specific horseradish peroxidase-conjugated secondary antibody, the probed 
PLY was detected using ECL Plus Western Blotting reagent and a Fluorchem Q machine.  
 
 
Fig. 19: Actin Spin Down Assay 
(schematic). 
 
 
2.10.5 Enzyme-linked sorbent assays (ELSAs) 
F96 Cert. Maxisorp Immuno plates were coated with PLY variants (20 μg/ml) overnight at 4°C. 
Unspecific binding sites were blocked with 10% fetal calf serum (FCS) for 1 h. G-actin was 
added in a concentration of 20 μg/ml, Arp2/3 protein complex in a concentration of 4 µg/well 
(80 µg/ml). After 2 hours incubation at room temperature (RT), the wells were washed 3 times 
with 1x PBS-T 0.05% (PBS, Tween-20). Anti-actin or anti-Arp antibodies (1:1000 or 1:500 in 
PBS) were incubated for 1 h at room temperature. HRP-conjugated secondary antibody was 
applied for 1 h in a 1:1000 dilution in PBS, and the reaction was visualized using 50 µl/well 
TMB substrate solution (30 minutes incubation). The reaction was stopped with 50 µl/well of 
0.18 M H2SO4. Substrate absorption was measured at 490 nm using an EL800 ELISA plate 
reader. 
 
Fig. 20: ELSA assay (schematic). 
Maxisorp Immuno plates were coated 
with PLY or its variants/fragments. 
Subsequently the amount of bound 
actin or Arp was detected with the help 
of an HRP-tagged antibody and 
measurement of absorption. 
 
 
2.10.6 Actin-pyrene polymerization assays 
One vial of 10 mg non-muscle platelet actin and the same amount of pyrene actin were 
resuspended in 50 µl double-distilled (MilliQ) water. The viscous solution was mixed (10% 
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pyrene actin) and diluted in general actin buffer (5 mM Tris-HCl, pH 8.0, 0.2 mM CaCl2) to a 
final actin concentration of 9 µM. The actin suspension was centrifuged at 150.000 x g for 
1.5 hours at 4°C to remove pre-formed actin aggregations. The supernatant was further 
diluted in general actin buffer to a final actin stock concentration of 3 µM. 
Polymerization of actin was measured by detection of actin-pyrene fluorescence in a 
fluorescence photometer (Luminescence Spectrometer), using a cuvette and an actin stock 
volume of 600 µl.  
 
 
 
Fig. 21: Time course of in 
vitro actin polymerization in 
the absence of effector 
proteins. 
(Source:[Alberts et al., 2008]*) 
 
Parameters for measurement: 
Excitation: 350 nm 
Emission: 407 nm 
Interval: 10 sec 
Cycles: 300 - 1800 
Integration time: 0.10 sec 
Excitation slit: variable (~ 5.0) 
Emission slit: variable (~ 6.5) 
(Single read and timedrive modus) 
Software: FL WinLab (Perkin Elmer) 
After measuring background fluorescence of actin for at least 5 minutes, additional 
components were added directly to the actin suspension. 
Concentrations of components: 
Actin polymerization buffer: 1x (10x stock) 
Arp2/3 protein complex: 50 nm 
Pneumolysin: variable 
VCA: 50 nm 
Inhibitory PLY-peptides: 10-fold concentration of PLY 
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2.10.7  Imaging of actin-rhodamine filaments 
Non-muscle actin, actin-rhodamine (actin human TRITC) and actin-biotin were diluted to a 
final stock concentration of 1 mg/ml in double-distilled water (MilliQ) and mixed in a ratio of 
65% : 25% : 10% (23 µM). Actin polymerization buffer was added to the actin mixture in a 1x 
final concentration. The mixture was incubated at 30°C for 1 hour for pre-formation of actin 
filaments. The 23 µM actin stock was subsequently diluted to a final stock concentration of 
200 nm in TIRF-buffer. 
TIRF-buffer: 
50 mM KCl 
1 mM MgCl2 
1 mM EGTA 
10 mM imidazole 
2 mM ATP 
0.2 mM β-mercaptoethanol 
4.5 mg/ml glucose 
4.3 mg/ml glucose oxidase 
0.7 mg/ml catalase 
Coverslip chamberslides or ibidi µ-slides were coated with 0,25 mg/ml NeutrAvidin® 
(streptavidin tag) for 2 minutes, in order to immobilize the actin-biotin containing actin fibers. 
NeutrAvidin® (5 mg/ml stock) was diluted in F-buffer. 
F-buffer: 
50 mM KCl 
1 mM MgCl2 
1 mM EGTA 
10 mM imidazole 
2 mM ATP 
0.2 mM β-mercaptoethanol 
Unspecific binding sites were subsequently blocked for 2 minutes with 1 mg/ml BSA (bovine 
serum albumin), which was diluted in F-buffer from a 10 mg/ml stock. After blocking, 30 µl of 
the 200 nm actin mix were added to the coated slide. After 2 minutes the unbound actin was 
removed by rinsing the site with TIRF-buffer, and the attached filaments were imaged 
immediately using fluorescent microscopy. 
Pneumolysin was used in a 1 µM end-concentration. For calcium supplementation PLY was pre-
incubated with 2 mM Ca2+ for 30 minutes at room temperature. 
VCA domain protein and Arp2/3 protein complex were used in a 60 nM end-concentration. 
 
 
2.10.8 Far Western Blotting (Overlay Blot) 
Actin (20 µg non-muscle platelet actin protein) and Rho (20 µg recombinant protein) were 
mixed with an equivalent amount of SDS-sample buffer, containing 2.5% β-mercaptoethanol, 
and boiled at 99°C for 3 minutes. The denatured proteins were electrophoresed on a 4-12% 
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Bis-Tris gradient gel at 120 V for one hour. Subsequently the proteins were blotted onto a 
PVDF membrane by using an iBlot® Dry Blot device (program 5, 7 minutes). After blotting the 
membranes were incubated in binding buffer (50 mM NaH2PO4, pH 7.5, 0.3% Tween-20) for 
30 minutes. The control membrane was further incubated in binding buffer for 2 hours, 
whereas the overlay-membrane was incubated in binding buffer containing 0.5 µg/ml PLY. 
Subsequently both membranes were washed 6 times in 0.1% PBS-T for 5 minutes each time. 
Unspecific binding sites on the proteins were blocked in 3% skimmed milk (in 0.1% PBS-T), 
and then incubated with a specific PLY antibody (1:1000) in PBS. Incubation with a HRP-
conjugated goat anti-mouse IgG (1:1000 in PBS) followed after a 3 times washing step, 10 
minutes each. Detection of the overlay was carried out on a FluorChemQ gel detection device, 
using ECL Plus Western Blot Detection reagent. 
 
 
2.10.9  FRET experiments 
Förster/Fluorescence resonance energy transfer (FRET) is able to reveal the proximity of two 
fluorescently labeled molecules over distances > 100 Å (1 - 10 nm), and thus can be used to 
investigate the affinity, binding or interaction between two proteins [Kenworthy, 2001]. 
Here FRET was used to show the co-localization of Atto488-tagged PLY and phalloidin-
Alexa555, using a luminescence spectrometer (photometer). The PLY-Atto488 stock was 
diluted 1:50 in PBS, resulting in a 5 µg/ml concentration of the fluorescence donor. Phalloidin-
Alexa555 was added in gradually dilutions (1:2.5, 1:3.3, 1:3.8) and the fluorescence energy 
transfer was measured between 500 and 600 nm. 
 
 
2.11  Giant unilamellar vesicle (GUV) approach 
GUVs comprise vesicles of 1-30 µm in diameter, consisting of a lipid bilayer, composed of a 
defined set of phospholipids [Baumgart et al., 2003; Colletier et al., 2002; Varnier et al., 
2010]. In this case the GUVs were composed of DOPC (1,2-Dioleoyl-sn-glycero-3-
phosphocholine), DPPC (1,2-dipalmitoyl-sn-glycero-3-phosphocho- line), and cholesterol in a 
ratio of 25% DOPC : 35% DPPC : 40% cholesterol. All components were diluted in chloroform. 
In order to obtain solvent-free membranes, 20 µl of the lipid solution were applied to a 
coverslip, and the dissolvent was removed completely by vacuum evaporation in an exsiccator. 
A ring, treated with grease, was placed around the dried lipids and then filled with D-sorbitol 
solution. In the Vesicle Prep Pro® device (Nanion), the GUVs were formed through electro-
swelling (hydration of a dry lipid film in an oscillating electric field). 
Liposomes, containing GFP-tagged PLY were composed of 40% DOPC and 60% DPPC. The 
lipids were dried at the bottom of an 8 ml tube for about 2 hours. Multi-lamellar vesicles were 
obtained by hydration of the film with 0.1 ml of 25 mM MOPS buffer, pH 8.5, containing 
0.3 nmol of the toxin. The tube was vortexed until the lipid film had peeled off from the tube 
surface. To break the multi-lamellar vesicles into mono-lamellar, ten cycles of freezing (liquid 
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nitrogen) and thawing (30°C water bath) were applied. The sample was then diluted to 1 ml in 
25 mM MOPS buffer. The size of liposomes was homogenized by extrusion by passing the 
sample 10-fold through a 200 nm pore polycarbonate filter, or by centrifugation. Carriage of 
PLY-GFP from the liposomes into the GUVs was achieved by cold-fusion (4°C over night). 
Depletion of extra-vesicular PLY-GFP was achieved by incubation of the liposome/PLY-GFP 
solution with cholesterol containing liposomes (composed of DOPC, DPPC). Free, non-
encapsulated PLY was captured by incubation for 2 hours on a shaker platform with a 
cholesterol-containing trap, which consisted of a dried multi-lamellar film of cholesterol-
containing lipid mixture as was used for the GUVs, and centrifuged to eliminate all big lipid 
sheets containing the bound PLY and stained fluorescent green (due to PLY-GFP). The liposome 
mixture was tested for cytotoxicity and toxin binding, which demonstrated a complete lack of 
free PLY. The fused GUVs demonstrated proper PLY-GFP staining localized on the surface of the 
GUV. To verify the orientation of the PLY-GFP on the GUVs‟ surface (which was expected to be 
on the inside, and thus the GFP should be hanging inside due to its tagging to the C-terminal 
of the toxin), we incubated GUVs with a strong quencher (trypan blue). The trypan blue should 
have quenched all the GFP fluorescence given that the toxin binds from the outside of the 
GUV, but the GFP fluorescence remained unchanged. 
For actin polymerization experiments, the GUVs with or without PLY were incubated with 
rhodamin-labeled G-actin in a final mix containing 7.5 μM G-actin, 160 nM Arp2/3 complex and 
1 mM ATP/Mg2+ containing actin polymerization buffer [Colletier et al., 2002]. 
Actin-TRITC was prepared freshly, by dilution of 10 µg in 30 µl ddH2O (MilliQ). The imaging 
sample, which was applied to an ibidi µ-slide, was composed of: 
22 µl aqua purificata 
15 µl actin-TRITC 
5 µl 10x actin polymerization buffer 
8 µl Arp2/3 protein complex (0.5 µg/µl stock) 
Imaging was performed on the Leica SP5 confocal microscope. 
 
 
Fig. 22: Nanion Vesicle Prep Pro®. 
Generation of an electric field in the 
Vesicle Prep Pro device (A) leads to 
electro-swelling of the dried phospholipid 
mixture in a D-sorbitol solution, resulting 
in the formation of so called giant 
unilamellar vesicles (GUVs), with a 
diameter of 10-30 µm (B). (Source: 
www.nanion.de; 2011) 
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2.12 Cell border tracking assay 
In order to properly evaluate pneumolysin effects on the cell shape and movement behavior of 
astrocytes, a cell border tracking assay, using ImageJ software (version 1.43 for Windows, 
National Institute of Health, Bethesda, Maryland, U.S.), was established. 
After sequential imaging of astrocytes (live cell imaging approach), the pictures were 
processed with ImageJ and then one single spot of the cell border of an astrocyte was tracked 
throughout the whole image stack from time point zero to the end with the „manual tracking“ 
tool. 
 
 
Subsequently the length of the line was measured with the help of the “line” tool, comprising 
the distance of cell movement. Per field, at least 10 cells were evaluated with this method. The 
mean distance in µm and the SEM were calculated. Treated cells were compared to mock 
treated cells. 
 
 
2.13 Preparation and resealing of erythrocyte ghosts 
Erythrocyte ghost were prepared as described in [Prausnitz et al., 1993] with some 
modifications. Shortly, we utilized fresh human donor blood, incubated with EDTA to avoid 
coagulation. Following lysis with 5 mM PBS buffer, pH 8.5, the ghosts were thoroughly washed 
and loaded with 2 mM calcein in 5 mM PBS buffer, pH 8.5 for 30 minutes on ice, followed by 
 
Fig. 23: Displacement tracking of living 
cells. 
The cell border of a single cell (evaluation of 
~10 cells/field) was tracked throughout a 
whole time stack from 0 min (white mark in  
A) to the end (white mark in B) with the 
help of the manual tracking plugin of the 
ImageJ software, and the distance in µm 
was determined (C). 
(C) shows the merge of the first (grey) and 
last (red) image of the time stack and the 
spatial shift of the cell (arrow). 
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1 hour additional incubation with 25 μg/ml bovine Arp2/3 or 25 μg/ml rabbit non-specific 
purified IgG as a negative control. The ghosts were resealed in 40 mM PBS pH 7.4 at room 
temperature for 2 hours, thoroughly washed and incubated in the same buffer with PLY. 
Following incubation with PLY for 20 minutes at 37°C, the remaining intact resealed ghosts 
were pelleted and lysed and their calcein fluorescence compared with the corresponding 
control, not exposed to PLY. The concentration of PLY was titrated to achieve ~40-50% lysis 
within 20 minutes of 1% (v/v) red blood cell ghosts. The identical shape and size of all 
resealed ghosts was confirmed by confocal microscopy, as well as the complete loss of their 
calcein fluorescence upon lysis by PLY. 
 
 
 
Fig. 24: Schematic of erythrocyte preparation. 
Schematic presentation of the erythrocyte ghost 
preparation, including erythrocyte lysis, loading 
with calcein and Arp2/3 or IgG and subsequent 
resealing. 
 
 
 
2.14 Graphical and statistical analysis 
Graphical analysis was carried out with ImageJ, version 1.44f for Windows (National Institute 
of Health, Bethesda, MD, U.S.). 
Evaluations and statistical analysis were carried out with MS Excel 2007 and with GraphPad 
Prism, version 4.02 for Windows (Graph Pad Software, Inc.). 
 
 
 
 
 
 
 
 
*: “Copyright 2008 from Molecular Biology of the Cell by Alberts et al. Reproduced by 
permission of Garland Science/Taylor & Francis Books, LLC.”  
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2.15 Equipment and Materials 
2.15.1 Pneumolysin and plasmids 
Pneumolysin and all its fragments and mutants, as well as their GFP-tagged variants (all 
diluted in PBS) were friendly provided by Professor Timothy J. Mitchell and Jiangtao Ma at the 
University of Glasgow, Scotland. Atto488 labeling of pneumolysin was performed by Christina 
Förtsch, University of Würzburg, Germany. 
 
Wild-type toxin: 
 PLY-WT 
 PLY-eGFP 
 PLY-Atto488 
 
Mutants: 
 Δ6-PLY (Δ A146 R147, mutation in the unfolding domain 3) 
 Δ6-eGFP 
 W433F-PLY (Trp433→Phe mutation in the Trp-rich loop of domain 4) 
 
Fragments: 
 D123-PLY (domains 1, 2 and the unfolding domain 3) 
 D4-PLY (binding-domain 4) 
Plasmids Source  
pLifeAct-TagRFP 
 
 
 
 
 
ibidi 
 
pTagRFP-actin Evrogen 
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2.15.2 Materials, animals, equipment and software 
Devices/Material Manufacturer 
Autoclaves Systec (V 150), HMC (HV-110) 
Balance Kern  
Centrifuges (table top) Hettich, Eppendorf 
Chambered coverslips and coverglasses, 
µ-slides 
Nunc, BD Falcon, ibidi  
Exsiccator Roth  
ELISA plate reader BioTek (EL 800)  
Freezer Heraeus (Hera freeze, -80°C)  
Gel/WB detector FluochemQ, AlphaInnotech  
Glass cuvette Hellma Analytics  
Ice machine Scotsman (AF 200)  
Incubators Heraeus (Hera Cell 240), Memmert 
Instruments for cell preparation Roth, Hartenstein  
Labware (Cell culture flasks, pipettes, 
multi-well plates, bottle-top filters, etc.) 
Sarstedt, Roth, StarLab, Eppendorf, Millipore, BD  
Laminar flow cabinets (sterile) BDK Luft- u. Reinraumtechnik  
Maxi Sorp Plates Nunc, BD Falcon 
Orbital shaker  Biometra (WT 12), NeoLab  
pH meter Hanna Instruments  
Photometer Perkin Elmer Instruments, Luminescence 
Spectrometer LS 50B 
 
Pipettes Eppendorf, Gilson 
Plastic cuvettes Roth  
Power supply units Biorad (Power Pac 3000), Consort (EV 231)  
Precision Balance Sartorius  
Protein electrophoresis chambers Invitrogen (Life Technologies)  
PVDF membrane Millipore (Immobilon-P)  
Refrigerators  Liebherr  
Rotator Stuart (SB2)  
Stirrer Heidolph  
Syringes Braun 
Thermomixer Eppendorf  
Ultra centrifuge tubes Beckmann, Herolab  
Ultra centrifuges Beckmann  
Vacuum pump IlmVac  
Vesicle Prep Pro (GUV device) Nanion Technologies  
Water baths Memmert 
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Chemicals/Media/Proteins Manufacturer  
Alcohols, buffers, milk powder, acids, 
bases, DMSO, other chemicals 
Roth, Sigma, AppliChem, Sigma-Aldrich  
Aqua purificata Roth  
Cell Culture Media, D-PBS GIBCO, Invitrogen (Life Technologies)  
Cholesterol Sigma-Aldrich  
Coomassie® Brilliant Blue R250 Powder Serva Electrophoresis  
DOPC, DPPC (phospholipids) Echelon Inc.  
Fetal calf serum Pan Biotech  
Chromatography columns Bio Rad  
HEPES buffer GIBCO, Invitrogen  
LPS (Endotoxin) Lonza  
MilliQ water (double distilled water) Millipore filter unit  
Mowiol 4-88 Roth  
NeutrAvidin® (avidin) Invitrogen, Molecular Probes (Life Technologies)  
Paraformaldehyde Roth  
Penicillin/Streptomycin (liquid solution) GIBCO, Invitrogen (Life Technologies)  
Poly-L-lysine (PLO) Sigma-Aldrich  
Protease Inhibitor Cocktail Roche  
TMB substrate solution Pierce (ThermoScientific)  
 
 
 
 
Microscopes Manufacturer  
Binocular Motic Microscopes  
Bright-field light microscopes Leica, Motic Microscopes  
Fluorescent microscope (wide field, 
inverted) 
Olympus  
SP5 confocal microscope Leica  
 
 
 
 
Laboratory animals Provider  
C57BL/6 mice Janvier, France  
Sprague Dawley rats Janvier, France; CharlesRiver, Germany  
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Primary Antibodies Manufacturer  
Anti-actin (mouse monoclonal), IgG1 Santa Cruz  
Anti-Arp2 (rabbit polyclonal), IgG Abcam  
Anti-Arp3 (mouse monoclonal), IgG1 Santa Cruz  
Anti-GFAP (rabbit polyclonal) Zymed® Laboratories (Invitrogen 
Immunodetection) 
 
Anti-p21-ARC (rabbit polyclonal), IgG Santa Cruz  
Anti-p41-ARCb (rabbit polyclonal), IgG Santa Cruz  
Anti-PLY (mouse monoclonal), IgG1, 
IgG2b 
Santa Cruz, Abcam  
Anti-Rac (rabbit polyclonal) Cytoskeleton Inc.  
Anti-Rac1/2/3 (rabbit polyclonal), IgG Cell Signaling  
Anti-Rho (mouse monoclonal) Cytoskeleton Inc.  
Anti-Vinculin hVIN-1 (mouse monoclonal), 
IgG1 
GeneTex Inc.  
 
 
Secondary Antibodies Manufacturer  
CyTM3-conjugated AffiniPure F(ab„)2 
fragment goat anti-mouse IgG 
Jackson Immuno Research 
Laboratories Inc. 
 
CyTM3-conjugated AffiniPure F(ab„)2 
fragment goat anti-rabbit IgG 
Jackson Immuno Research 
Laboratories Inc. 
 
Fluorescein (FITC)-conjugated AffiniPure 
F(ab„)2 fragment goat anti-rabbit IgG 
Jackson Immuno Research 
Laboratories Inc. 
 
Fluorescein (FITC)-conjugated AffiniPure 
F(ab„)2 fragment goat anti-mouse IgG 
Jackson Immuno Research 
Laboratories Inc. 
 
Peroxidase-conjugated AffiniPure goat 
anti-mouse IgG 
Jackson Immuno Research 
Laboratories Inc. 
 
Peroxidase-conjugated AffiniPure goat 
anti-rabbit IgG 
Jackson Immuno Research 
Laboratories Inc. 
 
 
 
Actins Manufacturer  
Actin-biotin Cytoskeleton Inc.  
Actin-pyrene (pyrene muscle actin) Cytoskeleton Inc.  
Actin-TRITC (rhodamine) Cytoskeleton Inc.  
Non-muscle actin (human platelet) Cytoskeleton Inc.  
Pre-formed actin filaments  
(rabbit skeletal muscle) 
Cytoskeleton Inc.  
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Commercial Kits Manufacturer  
Actin Binding Protein Biochem Kit Cytoskeleton Inc.  
Actin Polymerization Biochem Kit Cytoskeleton Inc.  
Active Rac1 Pull-Down and Detection Kit ThermoScientific  
BCA Protein Assay Kit Pierce (ThermoScientific)  
Cytoskeleton Isolation and Assay Kit Cytoskeleton Inc.  
Limulus Amebocyte Lysate Kit Lonza  
MagnetofectionTM PolyMag Oz Biosciences  
Rac Activation Assay Kit Cell Biolabs Inc.  
Rac1 Activation Assay Biochem Kit Cytoskeleton Inc  
Rho Activation Assay Biochem Kit Cytoskeleton Inc.  
SDS-PAGE equipment Manufacturer  
Gels 
NuPAGE 4-12% Bis-Tris Gels 
Anamed VarioGel 4-12% 
 
Invitrogen (Life Technologies) 
Anamed 
 
NuPAGE MOPS SDS buffer Invitrogen, Anamed  
NuPAGE Sample loading buffer Invitrogen, Anamed  
NuPAGE Antioxidant Invitrogen  
NuPAGE Sample reducing agent Invitrogen  
NuPAGE Transfer buffer Invitrogen  
Molecular weight markers: 
SeeBlue® Plus Prestained Standard 1x 
PAGE Ruler Prestained Protein Ladder 
Biotinylated Protein Ladder 
 
Invitrogen 
Fermentas 
Cell Signaling 
 
Novex® Semi-Dry Blotting Device Invitrogen  
iBlot® Dry Blot Device Invitrogen  
iBlot® Gel Transfer Stacks PVDF Mini Invitrogen  
ECL Plus Western Blotting Detection 
System 
GE Healthcare, AmershamTM  
Components for actin assays Manufacturer  
Actin Polymerization Buffer (10x) Cytoskeleton Inc.  
Arp2/3 protein complex (bovine brain) Cytoskeleton Inc.  
ATP (Adenosine tri-phosphate) Cytoskeleton Inc.  
General Actin Buffer Cytoskeleton Inc.  
WASP-VCA Domain-GST protein Cytoskeleton Inc.  
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Cell active 
components/Inhibitors/fluorophores 
Manufacturer  
Atto488, Atto561 Atto Tec GmbH  
C3bot Transferase Protein (bacterial 
recombinant) Rho inhibitor 
Cytoskeleton Inc.  
Calcein Invitrogen, Molecular Probes  
Cellular LightsTM Intracellular Targeted 
Fluorescent Proteins 
Baculovirus PM-GFP 
Baculovirus Actin-GFP 
Invitrogen, Molecular Probes  
(Life Technologies) 
 
Cytochalasin D Calbiochem  
Hoechst Stain Invitrogen, Molecular Probes  
NSC23677 Rac1 inhibitor Calbiochem  
Phalloidin-Alexa Fluor® 488 
Phalloidin-Alexa Fluor® 555 
Invitrogen, Molecular Probes  
Propidium Iodide Nucleic Acid Stain Invitrogen, Molecular Probes  
 
 
Inhibitory peptides Manufacturer  
Peptide I 
YGQVNNVPAR 
PanaTecs  
Peptide II 
MQYEKITAHS 
PanaTecs  
Peptide III 
MEQLKVKFGS 
PanaTecs  
Peptide IV 
RPLVYISSVA 
PanaTecs  
Peptide V 
YGRQVYLKLE 
PanaTecs  
Peptide VI 
MANKAVNDFILAMNYDKKKLLTHQG- 
ESIENRFIKEGNQLP 
Caslo Laboratories  
 
 
Application Software  
ELSA assays Gen5TM (BioTek)  
Fluorescence photometer measurements WinLab (Perkin Elmer)  
Image analysis ImageJ (NIH)  
Imaging Cell^M (Olympus), LAS AF (Leica)  
Statistics, Evaluations GraphPad, Inc. (Prism), MS Office   
Western Blot detection AlphaView® (AlphaInnotech)  
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2.15.3 Buffers and solutions 
Phosphate buffered saline 10x (PBS): 
1368 mM NaCl 
26.8 mM KCl 
101.4 mM Na2HPO4 
17.6 KH2PO4 
pH 7.3 
 
 
 
PBS-T 0.1%: 
1x PBS 
0.1% Tween-20 
 
 
 
Blocking solution (Western Blots): 
PBS-T 0.1% 
3-5% skimmed milk powder 
 
 
 
Coomassie blue staining solution: 
0.1% brilliant blue 
50% methanol 
10% acetic acid 
40% dH20 
 
 
 
Paraformaldehyde fixing solution: 
450 ml dH2O at 60°C 
20 g PFA 
5 drops 2N NaOH 
50 ml 10x PBS 
pH 7.2 
 
 
 
Poly-L-ornithine coating solution: 
0.15 M (3.71 g) boric acid 
0.025 mg/ml (100 mg) PLO 
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Mowiol 4-88 mounting solution: 
2.4 g Mowiol 
6 ml ddH2O 
6 g glycerol 
12 ml 0.2 M Tris-HCl pH 8.5 
2.5% DABCO 
 
 
Calcium-free imaging buffer: 
135 mM NaCl 
2 mM MgCl2 
4 mM KCl 
5 mM HEPES 
pH 7.3 
 
 
Calcium-containing imaging buffer: 
135 mM NaCl 
2 mM MgCl2 
2 mM CaCl2 
4 mM KCl 
5 mM HEPES 
pH 7.3 
 
 
Binding buffer (Overlay blotting): 
50 mM NaH2PO4, pH 7.5 
0.3% Tween-20 
 
 
Cell lysis buffer: 
50 mM Tris, pH 7.5  
10 mM MgCl2  
0.5 M CaCl  
2% Igepal 
 
 
Wash buffer: 
25 mM Tris, pH 7.5 
30 mM MgCl2 
40 mM NaCl 
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General actin buffer: 
5 mM Tris-HCl pH 8.0  
0.2 mM CaCl2 
 
 
Actin polymerization buffer: 
500mM KCl  
20mM MgCl2  
10mM ATP 
 
 
TIRF buffer: 
50 mM KCl 
1 mM MgCl2 
1 mM EGTA 
10 mM imidazole 
2 mM ATP 
0.2 mM β-mercaptoethanol 
4.5 mg/ml glucose 
4.3 mg/ml glucose Oxidase 
0.7 mg/ml catalase 
 
 
F-buffer: 
50 mM KCl 
1 mM MgCl2 
1 mM EGTA 
10 mM imidazole 
2 mM ATP 
0.2 mM β-mercaptoethanol 
 
 
Cell lysis/cytoskeleton stabilization buffer: 
50 mM PIPES pH 6.9 
5 mM MgCl2 
5 mM EGTA 
20% v/v glycerol 
0.2% v/v Nonidet P40 
0.2% v/v Triton X-100 
0.2% v/v Tween 20 
0.01% 2-mercaptoethanol 
0.001% Antifoam C 
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3 RESULTS 
3.1 Determination of the astroglial nature of cells 
 
 
Fig. 25: Primary mouse astrocytes. 
A. GFAP-staining shows the astrocytic nature and 
abundance of astrocytes in the culture. 
B. GFAP-staining also reveals the star-shaped phenotype of 
astrocytes, which partly bear long processes. Scale bars: 
10µm; anti-GFAP staining of fixed astrocytes, visualized by 
epi-fluorescent microscopy; 20xmagn. 
 
 
After isolation of astrocytes from mice or rat brains, the cells were cultured for two weeks in 
flasks and for investigation they were re-seeded in chambered cover-glasses or chamberslides 
(all coated with Poly-L-ornithine). In order to determine the astro-glial nature of the cells in 
use, the Glial Fibrillary Acidic Protein (GFAP), which is a specific component of intermediate 
filaments of astrocytes, was visualized by tagging with a specific anti-GFAP antibody in PFA-
fixed cells (immunocytochemistry). 
Fluorescent microscopy of the fixed samples revealed a strong GFAP staining and abundance of 
GFAP in the majority of cells (Fig. 25 A), which also showed typical characteristics of 
astrocytes, e.g. star-shape. Comparison of Fig. 25 with Fig. 15 reveals that astrocytes adapt 
different phenotypes in brain tissue (Fig. 15) and in culture (Fig. 25). Whereas astrocytes 
appear highly branched when connected with neurons, in culture they develop a broad 
phenotype (Fig. 25 B) leading to establishment of an astrocytic monolayer (as depicted in Fig. 
26/Fig. 28).  
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3.2 Definition of sub-lytic concentrations of pneumolysin (PLY) 
 
Fig. 26: Lytic capacity of PLY. 
A/B. Permeabilization of cells judged by propidium iodide (PI) staining. A high number of PI-positive cells 
represent microglia as indicated by the white arrows. The permeabilized cells are round and immobile. 
Scale bars: 20 µm.  
C. Permeabilization curves of astrocytes following challenge with different concentrations of PLY (0.05 - 
0.5 µg/ml);  n=3 experiments, the values represent mean ± SEM. 
 
 
This study was set to investigate the effects of the bacterial protein toxin pneumolysin on 
primary astrocytes under physiological conditions. In the liquor of patients suffering from 
pneumococcal meningitis, concentrations of PLY range between 0.001 and ~0.2 µg/ml [Spreer 
et al., 2003]. As this study used in vitro and not in vivo conditions, it had to be determined 
which concentrations of the toxin had lytic effects on the astrocytes. In this context it was only 
distinguished between lytic (permeabilized) and non-lytic (non-permeabilized), as a transient 
macro pore state could not be excluded. Therefore propidium iodide was added to mock-
treated and PLY-treated cells, and the number of permeabilized cells within a time lapse was 
determined.  
The astrocytes were challenged with increasing concentrations of PLY (0.05-0.5 µg/ml). 
Independent of the concentration, the permeabilization of cells occurred in a time lapse of 0 to 
40 minutes. With an increase of the concentration the halftime of permeabilization dropped 
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from ~22 minutes (0.05 µg/ml) to ~6 minutes (0.5 µg/ml). At a concentration of 0.1 µg/ml of 
PLY, 90% of cells were intact after 40 minutes from the time point of toxin application. 
Additionally many of the PI-positive cells were identified as microglia, which crawl on top of 
the astrocytic layer and have a clearly different morphology and a higher motility compared to 
the astrocytes (Fig. 26). Dead cells demonstrated a lack of motility and a rounded morphology. 
At higher concentrations (0.5 µg/ml) also many of the astrocytes in the monolayer were PI-
positive, with rounded cell bodies and without processes [Förtsch et al., 2011]. 
For all further investigation of PLY effects on primary astrocytes a toxin concentration of 
0.1 µg/ml (first toxin charge) and later 0.2 µg/ml (second toxin charge) was used (see Method 
part, chapter 2.2), latter in order to guarantee an equivalent rate of active toxin molecules 
within the treatment solution. 
 
 
3.3 Investigation of effects of sub-lytic PLY concentrations on astrocytes 
and the cytoskeleton 
Astrocytes were seeded on chambered coverglasses in a density providing the cells the 
possibility to build up inter-cellular contacts and a loose monolayer. The cells were investigated 
using either transmission light imaging or fluorescent imaging, latter after transfection or 
transduction with fluorescent proteins or probes.  
Observation of control cells revealed minimal movement, with minimal displacement in a 
certain time frame. Slight membranous changes and fluctuations could be observed on the 
quiescent cells (Fig. 27). 
 
 
 
 
Fig. 27: Behavior of mock-treated astrocytes. 
Mock treated cells show no or slightly cell shape 
changes or displacement phenomena as judged by 
GFP-staining of the plasma membrane of astrocytes 
and subsequent time lapse imaging. Scale bars: 10 µm 
fluorescence microscopy, 20xmagn. 
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Application of 0.2 µg/ml PLY to the cells led to distinct morphological changes and to changes 
in the cell position. The contraction of the cell body induced cell displacement (up to 7 µm in 
distance from the original position), distraction, and disruption of the monolayer (Fig. 28 A). 
 
 
Fig. 28: Effects of sub-lytic amounts of PLY (0.2 µg/ml) on primary astrocytes. 
A. Challenge of the cells with PLY leads to severe cell shape remodeling. The shrinkage and displacement 
of cells induces the formation of big holes in the cell monolayer (indicated by the red arrows). The 
displacement of the astrocytes also reveals the highly motile, smaller microglia, which are tightly 
associated with the astrocytic monolayer (green arrow). Scale bars: 20 µm; transmission light, time-stack 
imaging of astrocyte culture; 20xmagn. 
The graph depicts the size of the holes in mm2; n=6, the value represents the mean ± SEM;  
B. Application of sub-lytic amounts of PLY reveals the outlining of cell nuclei (white arrows), probably 
induced by actin cytoskeleton contractions. Scale bar: 20 µm. 
C. GFP-staining of the plasma membrane of primary astrocytes reveals the formation of membrane 
blebbings, visible continuously through the whole time stack. Scale bar: 10 µm. 
D. Loosening of cell contacts and cell retraction induces holes or open spaces (red arrow). During the 
cellular displacement certain actin structures are retained (green arrow), while in general there occurs a 
decrease in actin density and actin structure complexity; visualization of actin with LifeAct-TagRFP, 
fluorescence imaging, 60xmagn. 
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Furthermore, an increase in cytoplasmic granules and stronger membranous fluctuations 
(wave-like) were observed, and the outline of the cellular nuclei became visible (Fig. 28 B).  
Fluorescent labeling of actin with the help of LifeAct-TagRFP (red fluorescent protein) gave 
further insight into the cell displacement events. While the cells retracted, cell-cell contacts 
were loosened, and whereat in general a decrease in actin density and actin structure 
complexity was be observed, certain actin structures within the cells were retained (Fig. 28 D). 
A very broad effect of toxin treatment was the so called membrane blebbing, a detachment of 
the plasma membrane from the cell body, which could easily be observed with probing the 
plasma membrane with GFP (Cellular Lights, PM-GFP) (Fig. 28 C). 
 
 
 
Fig. 29: Phases of cell displacement. 
A. Cell displacement plot demonstrates a rapid initial phase (0-5 min) after treatment of astrocytes with 
0.2 µg/ml PLY, and a slower, more moderate displacement thereafter. 
B. Increase in cell displacement following PLY challenge. The increase in the second phase (5-30 min) is 
much lower than the displacement in the early phase before 5 minutes, indicated by the displacement 
difference; p<0.001, n=10 cells. The values represent the mean ± SEM. 
 
 
Plotting of the cell-displacement (with the help of the displacement tracking assay, as 
described in the methods part) demonstrated a rapid initial phase (a few seconds to 
5 minutes) with continuing but slower changes in the late period.  
The shift in position within the first 5 minutes was very distinct (up to 6 µm from the original 
position), the changes in the following minutes were less severe and slower (only additional 1-
2 µm shift in position).  
 
Fluorescent labeling of actin with RFP via transfection with the pLifeAct-TagRFP or the 
pTagRFP-actin vectors allowed as well a more detailed investigation of the cytoskeletal 
changes in the early phase after toxin application. High-resolution z-stack imaging revealed 
cell shrinkage (as seen before in transmission light live cell imaging), actin bundle 
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deformation, and cortical actin bundling towards the cell core, while the Atto488-tagged toxin 
aggregated on the plasma membrane, and thus on the cell surface (Fig. 30 A). The decrease of 
actin density lead to mechanical imbalance, with the actin collapse occurring predominantly in 
horizontal direction where the tension powers are known to be highest [Pourati et al., 1998] 
(Fig. 30 B). The shrinkage caused a filopodia-like phenotype of the cells, which were keeping 
their adherence to the coverslip bottom (indicated in Fig. 33). 
 
 
 
Fig. 30: Actin cortex collapse. 
Confocal high-resolution z-stack imaging of actin (visualized with LifeAct-TagRFP, green pseudo-coloration) 
and PLY (Atto488-tagged, magenta pseudo-coloration).  
A. Within 40 seconds the actin cortex is severed from the plasma membrane and collapses in direction of 
the cell core. The membrane is indicated by the magenta puncta, comprising toxin aggregations on top of 
the cell. 
B. Z-projection displays actin structure contraction in horizontal direction where biomechanical tensions 
are highest. The collapse happens in direction of the cell core, and thus leads to a vertical enlargement of 
the cell whereat cellular adhesions are preserved. 
 
 
 
In the context of the observed cellular changes there also occurred an increase in the number 
and size of focal adhesions, which established from small, but defined focal points and 
developed upon PLY treatment in a time frame of about 30 minutes. FAs were visualized by 
vinculin immuno-staining in PFA-fixed cells (Fig. 31). 
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Pre-treatment of the cells with cytochalasin D, a potent inhibitor of actin polymerization, and 
thus an actin cytoskeleton degrading chemical effector, potently inhibited most cell 
modifications induced by PLY. Movement and distraction of cells were completely abolished. 
Membrane blebbing, however, was not diminished by the mycotoxin, but enhanced (Fig. 32). 
The cells revealed in general a different phenotype, which derived from actin cytoskeleton 
degradation. 
 
Fig. 31: Development of focal adhesions. 
During the cytoskeletal changes and cell shape 
remodeling induced by PLY challenge, distinct 
focal points (depicted in the mock-treated cells) 
expand to focal adhesions (FAs), which appear 
as longish aggregations of vinculin in 
immunocyto-chemistry staining. Scale bars: 
10 µm; 
confocal microscopy of fixed astrocytes after 
staining with a vinculin antibody; 63xmagn. 
 
Fig. 32: Pre-treatment 
of astrocytes with 
cytochalasin D. 
4 µM cytochalasin D lead to 
actin destruction in primary 
astrocytes, which abolishes 
displacement, and enhances the 
formation of membrane 
blebbing (right panel). Scale 
bars: 10 µm; epi-fluorescence 
imaging of astrocytes 
transduced with a Baculovirus-
PM-GFP construct; 20xmagn. 
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Visualization of actin, again with the help of the pTagRFP-actin vector allowed a closer look on 
the altered actin morphology induced by PLY treatment. Quiescent astrocytes showed a strong 
abundance of stressfibers, which spanned the cells (indicated by the green arrow in Fig. 33).  
In a time frame of about 10 minutes after toxin application, those filamentous actin structures 
were degraded to a mesh-like phenotype of actin, probably comprising undefined actin 
aggregations or branched actin structures throughout the cell and around the nucleus. As 
mentioned before, the cells did not detach from the bottom of the culture slide, indicated by 
the establishment of filopodia-like structures (white arrows in Fig. 33). 
 
 
 
Fig. 33: Actin changes induced by PLY 
challenge. 
0.2 µg/ml pneumolysin induces a change of 
actin morphology in astrocytes. Witin 
10 minutes the filamentous actin is degraded 
to an actin mesh (both phenotypes indicated 
by green arrows). While the cells shrink, 
they keep attached to the bottom of the 
slide, which results in the establishment of 
filopodia-like structures (white arrows). 
Scale bar: 10 µm; Confocal fluorescence 
imaging after transfection with the pTagRFP-
actin vector; 63xmagn. 
 
 
To investigate the influence of calcium influx in the cell shape changes, the astrocytes were 
imaged (time lapse, transmission light imaging) in calcium free HEPES-buffer (see methods). 
The cells that were treated with 0.2 µg/ml PLY displayed a significantly higher displacement 
than the mock-treated cells. The displacement was comparable to the displacement of cells 
that were imaged in Leibovitz‟s medium. 
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Fig. 34: Displacement of astrocytes in 
calcium-free buffer. 
Calcium-free conditions do not alter the range 
of cell displacement upon PLY treatment 
(0.2 µg/ml); ***p<0.001, n=30 cells from 
4 experiments; the values represent the 
mean ± SEM. 
 
 
 
3.4 Involvement of the small GTPases Rac1 and RhoA in the effects 
induced by pneumolysin 
The dependence of the cytoskeletal changes on small GTPases was tested both biochemically, 
and in the cellular system. In the pull down assays (small GTPase activation assays) the 
activation levels of Rac1 and RhoA were compared to the levels in mock treated cells (primary 
astrocytes). Furthermore the levels of activated GTPases were normalized to the levels of total 
Rac and Rho in the cells.  
 
Fig. 35: Involvement of Rac and Rho in 
the cellular changes induced by PLY. 
A. Pull-down analysis of activated Rac1 
demonstrates an increase at 5 minutes 
following PLY challenge (0.2 µg/ml). 
Pull-down analysis of activated RhoA 
demonstrates an increase at 15 minutes; 
n=3. 
B. Increase in displacement (vs. mock) 
following a 0.2 µg/ml PLY challenge is not 
affected by NSC23766 (Rac1 inhibitor) and 
C3bottransferase (Rho inhibitor) in the first 
5 minutes. In the late window of 
displacement (5-30 min), the Rac1 inhibitor 
significantly reduces the displacement; *p< 
0.05, n=30 cells from 4 experiments; all 
values represent the mean ± SEM. 
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Rac1 was upregulated after 5 minutes following PLY treatment, reaching a maximum of 
activation after 15 minutes. RhoA activation followed the same kinetics as Rac1 activation, but 
with generally lower amounts. Furthermore, RhoA activation stayed unchanged until 
15 minutes after toxin application. After 30 minutes both GTPases reached a lower activation 
degree (Fig. 35, A). In the time frame of 0 to 5 minutes no activation could be observed. 
For additional clarification a specific Rac1 inhibitor (NSC23677) and a general Rho inhibitor 
(C3bot transferase) were used. The displacement increase of inhibitor-treated cells after PLY 
challenge was compared to the untreated cells. Inhibition of Rho had no influence on the cell 
modifications induced by PLY, neither in the early phase (0-5 min), nor in the late phase (5-
30 min). Rac1 in contrast was not changing PLY induced effects in the first 5 minutes, but 
significantly reduced displacement in the late phase, compared to untreated or C3bot-treated 
cells (Fig. 35, B). Cellular uptake of C3bot was affirmed by a significantly different phenotype of 
astrocytes compared to untreated cells (data not shown). 
 
 
3.5 Application of giant unilamellar vesicles (GUVs) for investigation of 
transmembranous PLY effects 
The GUV system (giant unilamellar vesicles), which comprises a system of artificial membranes 
(vesicles consisting of a lipid-bilayer, with a diameter of about 10-30 µm), was used to 
investigate a possible direct interaction between pneumolysin and actin, while limiting the 
components to phospholipids, cholesterol, rhodamine-labeled actin (actin-TRITC), GFP-tagged 
toxin and Arp2/3 protein complex. The distribution of components, however, was inverted to 
the cellular system, with the cellular factors outside the GUVs and the toxin from within the 
GUVs. Loading of the vesicles with PLY was achieved by cold fusion (4°C) with a liposome 
carrier (schematic Fig. 36, A). Extra-vesicular PLY was inactivated with a cholesterol trap. Cells 
treated with the GUV solution showed no changes and no permeabilization, indicating 
successful depletion of PLY (data not shown). 
Actin-rhodamine was resolved in general actin buffer, providing Arp2/3, ATP and Mg2+, which 
allowed spontaneous nucleation and polymerization of actin, both in the suspension, and 
around the GUVs (Fig. 36, B, mock). Such aggregations were visible as small clusters of 
rhodamine after 30-60 minutes, and occurred also around the control GUVs, which contained 
no PLY. The presence of wild-type PLY, however, both accelerated, and increased the actin 
aggregation on the GUV surface, with accumulation of PLY-GFP co-localizing with the biggest 
actin-rhodamine clusters (Fig. 36, B, WT-PLY). 
The non pore-forming mutant Δ6-GFP itself aggregated partially, but was not able to initiate 
actin clustering in a similar magnitude as the wild-type toxin (Fig. 36, B, d6-PLY).  
The stabilization of actin was measured by comparison of the amount of pixel with a certain 
intensity. All values were normalized to the background comprised by rhodamine fluorescence. 
The GUVs, which contained the WT-PLY, showed the highest number of pixel with an intensity 
above the background.  
 
RESULTS 
63 
  
 
 
Fig. 36: GUV approach. 
A. Schematic presentation of the GUV experimental approach. The toxin and the actin together with 
the Arp2/3 complex localize on both sides of the lipid bilayer in a manner corresponding to the cell 
membrane. 
B. Aggregation of actin-rhodamine on the surface of GUVs in close proximity with the PLY-GFP 
clusters of wild-type PLY (WT-PLY; arrows), but not in the mock sample or the non-pore forming 
delta6-PLY (d6-PLY) GUVs. Scale bar: 10 μm 
C. Cumulative histogram of the pixel intensity distribution along the GUV surface normalized to the 
average actin-rhodamine intensity outside the GUV. The histogram represents cumulative data of 15-
20 GUVs of one representative experiment. The experiment was replicated 3 times. 
D. Increased actin aggregation (as measured by the increased rhodamine intensity above the actin 
background) in the WT-PLY GUVs; *p <0.05, values represent the mean ± SEM, n =15-20 GUVs of 
one representative experiment, replicated 3 times. 
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The actin accumulation around the GUVs, which contained the Δ6 mutant, was comparable to 
the clusters that occurred around the un-loaded GUVs, and which were due to spontaneous 
actin nucleation in the suspension (measurement of pixel intensity depicted in Fig. 36C, D). 
WT-PLY was able to stick through the lipid bilayer and aggregate actin. Arp2/3 was present in 
the system. It nucleated actin in absence of VCA, however, only in combination with WT-PLY 
(Fig. 36, B). 
 
 
3.6 Investigation of PLY-actin interaction 
3.6.1 Spin-down assays 
The capacity of pneumolysin to directly interact with actin and influence the actin status was 
investigated mainly with the help of biochemical approaches, both cell-based, and purely 
biochemical, using human platelet actin and isolated ABPs (actin binding proteins). 
When cells were treated with PLY (0.2 µg/ml) and the cytoskeleton subsequently isolated and 
spun down by ultracentrifugation, the toxin could be detected in the pellet fraction (Fig. 37). At 
a speed of 150.000 x g, a 53kD protein (such as PLY) only settles down in the pellet when 
bound to a protein with higher molecular weight. Actin filaments and tubulin filaments have a 
weight of a multiple of 42 kD for actin and 55 kD for tubulin, respectively. 
 
 
Fig. 37: Cytoskeleton Isolation Assay. 
PLY co-sediments with the cell cytoskeleton during 
ultracentrifugation. Degradation of actin (AD) or tubulin 
(TD) or both (A/TD) decreases the toxin amount in the 
pellet. (Western Blot, anti-PLY staining) 
 
 
Upon degradation of the actin or tubulin cytoskeleton, or both, there was less toxin found in 
the pellet fraction, meaning less toxin settling down in the pellet during ultracentrifugation. 
With less extend of cytoskeleton structures to bind to, the amount of detectable toxin became 
smaller. 
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Fig. 38: Actin binding and stabilization capacity of PLY. 
PLY co-settles with isolated actin during ultracentrifugation. 
A. Coomassie staining of the pellet fraction containing F-actin that co-precipitates with WT-PLY and 
weakly co-precipitates with Δ6-PLY, W433F-PLY and D4-PLY. D123-PLY overlaps with actin. 
B. Western Blot analysis of the co-precipitation of the D123-PLY confirms its presence in the pellet at 
~10 kD. 
C. PLY significantly stabilizes actin (F-/G-actin ratio from the precipitation assays); *p>0.05, n=5, values 
represent mean ± SEM. 
 
 
To clarify the capacity of PLY to bind to actin filaments (F-actin), an actin binding spin down 
assay was used, which reveals a possible co-precipitation of a certain protein together with 
actin. Isolated human platelet actin was incubated together with WT-PLY, the mutants (Δ6 and 
W433F), and the fragments (D123, D4), and subsequently ultracentrifuged. The supernatant 
fraction and the pellet fraction were electrophoresed and the gels stained with Coomassie. The 
proteins were blotted on PVDF membranes, and probed with a PLY antibody. The spin down 
assay revealed that every variant of pneumolysin was able to settle down together with actin 
in the pellet, indicating that every variant had the capacity to bind the toxin. The wild type 
toxin, however, bound actin with the highest affinity. All variants were detectable with 
Coomassie staining, except the D123 fragment, which has about the same molecular weight as 
actin, and thus was hidden behind the actin band (see Fig. 38, A). Domain 4 in contrast could 
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not be detected with the PLY antibody, as latter is specific for binding to the domain 123 
fragment (see Fig. 38, B). 
Densitometric analysis of the actin bands in the supernatant and pellet fractions revealed that 
incubation with PLY slightly shifted the G-actin/F-actin ratio in direction of fibrous actin, which 
indicates a stabilization of actin (Fig. 38, C). 
 
 
3.6.2 Actin-pyrene polymerization assays 
To further investigate a possible stabilization/nucleation capacity of PLY, an actin-pyrene 
polymerization assay was used. Pyrene develops fluorescence as soon as it polymerizes. Actin 
is only able to polymerize in the presence of ATP and Mg2+, both of which were provided in the 
polymerization buffer. The pyrene-actin in general actin buffer was monitored for 5 minutes 
and comprised background fluorescence. Addition of ATP and Mg2+ to the actin suspension lead 
to a slight increase of pyrene fluorescence. This phenomenon also occurred when PLY was 
added together with the polymerization buffer, whereat the fluorescence intensity was higher 
with PLY than with the buffer alone. The increase induced by PLY occurred in a dose-dependent 
manner (see Fig. 39). PBS, which comprises the solvent of pneumolysin, was not able to 
influence the fluorescence level. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 39: Actin stabilization capacity 
of PLY. 
Dose-dependent stabilization of actin-
pyrene (3 µM) by PLY (buffer 
supplemented with Mg2+ and ATP) as 
judged by measurement of fluorescence 
intensity increase. 100 nM of PLY are 
sufficient to increase the amount of 
polymerized actin. 
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3.6.3 Far Western Blotting 
The capacity of a protein to bind another protein, even if this one is partially degraded, can be 
easily detected with overlay blotting (also called Far Western Blotting [Hall, 2004]). Human 
platelet actin and RhoA recombinant protein (comprising the control) were electrophoresed, 
applied to Western blotting and the membranes were incubated together with (= PLY overlay) 
or without PLY. The subsequent staining with a PLY antibody displayed, that PLY was able to 
strongly bind actin, even in a partially degraded conformation. In contrast, there was no 
binding of PLY to the RhoA control protein (Fig. 40). 
 
 
 
 
Fig. 40: Overlay blot. 
Overlay and detection of PLY after 
electrophoresis and blotting of actin 
and RhoA. PLY shows a strong 
affinity to actin (vs. RhoA) even in a 
denatured confirmation of the 
protein. 
 
 
3.6.4 Enzyme-linked sorbent assays (ELSAs) 
G-actin binding was tested with the help of an enzyme-linked sorbent assay (ELSA). WT-PLY 
was linked to the bottom of a maxisorp plate and actin or FCS (control) was added. 
The bound actin was detected with the help of a primary actin antibody and a HRP-conjugated 
secondary antibody, which catalyzes, dependent on the amount of bound antibody, a 
calorimetric change in the TMB substrate (Fig. 20 displays a schematic of the assay). 
Only actin, and none of the proteins of the serum (FCS) were able to interact with PLY, which 
led to a higher absorption value in the test (Fig. 41).  
 
Fig. 41: Affinity of PLY to actin.  
Enzyme-linked sorbent assay. 
G-actin binding of PLY-WT in 
comparison to FCS; n=3, values 
represent the mean ± SEM. 
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3.6.5 Immunocytochemistry 
Confocal microscopy of pneumolysin-treated and subsequently PFA-fixed astrocytes indicated 
that PLY had a certain affinity to actin also in the cellular system. The actin cytoskeleton was 
visualized with the help of phalloidin-Alexa555. The cells were fixed at very early time points 
(in the range of 10 to 60 seconds) after PLY-Atto488 challenge, right in the state of 
membrane-binding, before the toxin was able to induce disturbance of the actin cytoskeleton. 
PLY was found to localize on the membrane in close vicinity to the actin cortex structures 
below the PM, decorating the actin bundles from this membrane-bound state (Fig. 42). The 
picture in the middle (lower panel) depicts the toxin aggregates on the membrane. The merge 
(“overlay”) shows the intimate proximity of both proteins. 
 
Fig. 42: Actin bundle decoration by PLY. 
Imaging of astrocytes demonstrates a co-
localization between F-actin (stained with 
phalloidin-Alexa555, green pseudo-coloration) 
and PLY (Atto488-tagged, magenta pseudo-
coloration) 60 s after toxin exposure (0.2 µg/ml) 
on the top of the cell. Scale bars: 10 µm. 
 
 
 
3.7 Investigation of PLY-Arp interaction 
3.7.1 Enzyme-linked sorbent assays (ELSAs) 
  
Fig. 43: Binding of PLY to the 
Arp complex and to Arp2. 
An ELSA (Enzyme-linked sorbent) 
assay demonstrates an increased 
binding affinity of PLY to the Arp2 
component of the Arp2/3 
complex, and compares the 
binding capacity of PLY to Arp2 in 
comparison to FCS; n=3, values 
represent the mean ± SEM. 
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Arp2/3 is a heptameric protein complex. Four components of the complex, namely Arp2, Arp3, 
p21 and p41 were tested for interaction with pneumolysin with the help of an enzyme-linked 
sorbent assay (ELSA). WT-PLY was linked to the bottom of a maxisorp plate, and the binding 
of Arp components, or Arp2 vs. FCS, respectively was judged by measurement of absorption 
(as described above). 
Only Arp2, and not Arp3 or p21/p41 of the Arp complex showed the capacity to significantly 
interact with WT-PLY (Fig. 43). Serum proteins (FCS) hat no capacity to interact with PLY. 
 
 
3.7.2 Immunocytochemistry 
 
Fig. 44: Co-localization of PLY and Arp2. 
Shortly after toxin exposure (<1min), PLY-Atto488 
(magenta pseudo-coloration) clusters in immediate 
vicinity or directly co-localizing with Arp2 structures 
(green pseudo-coloration); confocal z-stack imaging. 
Scale bar: 10 µm. 
 
 
Similar to the investigation of PLY-actin interaction, PLY was tested for its capacity to co-
localize with Arp2. Therefore, astrocytes were treated with PLY-Atto488 and subsequently fixed 
with paraformaldehyde (PFA). Arp2 of the Arp2/3 complex was visualized by tagging with an 
Arp2-specific antibody. The toxin was found to cluster rapidly (within the timeframe of 1 
minute) and very closely and partially overlapping with Arp2, which is depicted in the overlay 
of Fig. 44. 
 
 
3.7.3 Actin-pyrene polymerization assays 
Arp2/3 is a potent nucleator of actin, but requires activation by the VCA domain of WASP 
family proteins. The development of fluorescence increase in the presence of VCA is shown in 
Fig. 45. The fluorescence developed rapidly, reaching a higher maximal value in comparison to 
the activation of Arp by PLY.  
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In actin-pyrene polymerization assays, Arp2/3 protein complex alone slightly increased actin 
polymerization and thus fluorescence (Fig. 46 A, Actin+Arp). Arp in combination with PLY 
enhanced clearly the pyrene fluorescence (Fig. 46 A, Actin+Arp+PLY), similarly to the 
experiments without Arp (compare to Fig. 39), in a dose-dependent manner (Fig. 46 B). 
Thus, Fig. 46 A shows that PLY alone was able to only slightly stabilize actin, but to potentially 
activate Arp2/3, which lead to an increase in actin-pyrene fluorescence. 
 
 
Fig. 45: Arp2/3-mediated actin 
polymerization. 
Comparison of Arp2/3 activation by PLY 
(100 nM-1µM) and the cellular Arp2/3 activator 
VCA domain (50 nM). 
  
Fig. 46: Arp activation capacity of PLY. 
Comparison of actin polymerization by PLY, non-activated Arp2/3 (50 nM), and PLY-activated Arp2/3. 
Arp2/3 activation by PLY occurs in a dose-dependent manner, starting at low toxin concentrations 
(100 nM-1 µM PLY) already. 
A B 
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In the presence of VCA domain protein, the fluorescence showed the fastest and strongest 
increase, which is typical for actin nucleation by VCA-activated Arp. In presence of VCA and 
PLY the fluorescence reached the same maximum, but even faster, with the fluorescence curve 
showing a stronger gradient than the VCA curve (Fig. 47). 
 
 
 
 
3.7.4 Imaging of actin-rhodamine (TRITC-tagged)  
Coverslip chamberslides were coated with streptavidin, and pre-formed actin filaments, 
consisting of non-muscle actin, actin-rhodamine (actin-TRITC) and actin-biotin were applied to 
fluorescence imaging. Addition of 1 µM pneumolysin to the actin filaments did not change their 
morphology. The addition of Arp2/3 protein complex resulted in the Arp-specific branched actin 
structures. Here it was not relevant if Arp was activated by VCA or by PLY. 
 
 
Fig. 48: Fluorescent imaging of actin-rhodamine. 
PLY (1 µM) has the capacity to activate Arp2/3 (60 nM) in a similar mode as VCA (60 nM). The resulting 
actin structures (Actin+Arp2/3+PLY and Actin+Arp2/3+VCA; 200 nM actin) reveal a similar morphology; 
epi-fluorescent microscopy, 60x magn. 
 
Fig. 47: Additive effects of PLY 
in the activation of Arp2/3 by 
VCA. 
VCA (50 nM) and PLY (1 µM) work 
in a synergistic manner to activate 
Arp2/3 (50 nM), which results in 
an acceleration of actin nucleation. 
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3.8 Investigation of structural characteristics of PLY-actin and PLY-Arp2 
interaction 
3.8.1 Enzyme-linked sorbent assays 
 
 
 
Pneumolysin is a 4-domain protein, with its binding motif in domain 4 and domain 3 as 
unfolding domain. The availability of variants and fragments of the toxin allows a more 
detailed investigation of interaction of PLY with other proteins or the membrane. 
Application of ELSAs (enzyme-linked sorbent assays) clearly showed that only the wild-type 
toxin and the D123 fragment had the capacity to strongly interact with actin and Arp, whereas 
the binding domain (D4) and the Δ6 mutant, which cannot unfold properly in the membrane-
bound state, revealed less affinity to actin and Arp (Fig. 49, Fig. 50). 
 
 
 
 
Fig. 50: Structural properties of PLY-Arp2 
interaction. 
An ELSA (enzyme-linked sorbent) assay 
demonstrates an increased binding affinity of WT-
PLY and the 1-3 domains (D123-PLY) towards Arp2 
and reduced affinity of the Δ6-PLY mutant and the 
binding domain 4; n=3, values represent the mean 
± SEM. 
 
 
Fig. 49: Structural properties of PLY 
interaction with G-actin. 
An ELSA (enzyme-linked sorbent) assay 
demonstrates an increased binding affinity of WT-
PLY and the 1-3 domains (D123-PLY) towards G-
actin and reduced affinity of the Δ6-PLY mutant 
and the binding domain 4; **p<0.01 
***p<0.001, n=6, values represent mean ± SEM. 
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3.8.2 Actin-pyrene polymerization assays 
In order to gain a better insight into the structural prerequisites of interaction and binding 
between PLY and actin/Arp, single peptide sequences of the unfolding domain (D3) were used 
in actin-pyrene polymerization assays to check their possible influence on Arp-activation by 
PLY. The peptides have the following positions in D3: 
 
 
Fig. 51: Schematic of the unfolding domain of 
PLY. 
Domain 3 of PLY consists of 6 peptides, which 
refold into β hairpins that penetrate into the 
membrane. 
 
 
Adding the single peptides (I-VI) to actin, in combination with Arp, actin polymerization buffer 
and PLY, revealed no significant change in fluorescence increase. Only peptide II increased the 
fluorescence to a slightly higher maximal value. The effects of the peptides are depicted in Fig. 
52. 
 
 
Fig. 52: Investigation of structural 
properties of PLY-Arp interaction. 
Simultaneous incubation of Arp2/3 (50 nM) 
with PLY (1 µM) and the single peptides 
(10 µM) of the unfolding domain 3 does not 
alter actin polymerization kinetics. 
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3.8.3 FRET (Fluorescence resonance energy transfer)  
FRET experiments uncovered a significant fluorescence energy transfer between a PLY-
Atto488/Phalloidin-Alexa555 FRET pair (Fig. 53). An increase in phalloidin concentration 
quenched the PLY-Atto488 fluorescence in a concentration-dependent manner. 
 
Fig. 53: FRET measurement between PLY and 
phalloidin. 
Spectrophotometric analysis of the decrease in PLY-
Atto488 fluorescence after addition of phalloidin-
Alexa555, which is indicative of FRET and confirms an 
interaction between PLY and phalloidin. 
 
3.9 Influence of the Arp2/3 complex on pore formation - application of 
erythrocyte ghosts 
In order to examine the role of the PLY/Arp interaction on the capability of PLY to form lytic 
pores an erythrocyte system was used. This system avoided the interference of cell trafficking 
phenomena on the toxin‟s lytic capacity, as it is devoid of endo-/exocytotic events. The ghosts 
were depleted of ATP, and all other cytosolic components) and resealed after lytic emptying. 
 
 
Fig. 54: Influence of Arp2/3 on the lytic 
capacity of PLY. 
A. Confocal imaging of calcein-loaded 
resealed ghosts and z-profile reconstruction 
confirm the retained erythrocyte-like disc 
shape, proper resealing and equivalent size. 
Scale bar: 2 µm. 
B. Relative lytic capacity of 0.2 µg/ml PLY 
on calcein-loaded resealed ghosts, 
containing either the Arp2/3 complex, nor-
specific IgG or nothing. The enrichment with 
Arp2/3 enhanced the lytic capacity of PLY 
vs. the IgG-control; **p<0.01. Values 
represent mean ± SEM. 
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With the help of confocal imaging it was made sure that the resealed ghosts had retained the 
erythrocyte-like disc shape (Fig. 54 A). The different loading of the erythrocytes did not 
influence the shape. The experiments revealed that the lytic capacity of PLY in calcein-loaded, 
Arp2/3-enriched ghosts was significantly higher than in IgG-enriched or mock ghosts.
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4 DISCUSSION 
Bacterial meningitis is defined as an inflammation of the protecting membranes of brain 
and spinal cord, the meninges, with impact on the pia, the arachnoid and subarachnoid space, 
and remains the most common form of CNS infection in humans. It is associated with a severe 
clinical outcome, high case fatality rates, and high incidence rates of remaining neurological 
deficits (reviewed in [Kim, 2003]). It was supposed that the disease-related symptoms, such 
as brain edema (acute) and learning disabilities (chronic), derive from modulations induced by 
the bacteria and their effector proteins in the brain tissue, and additionally from the 
destructive force of immune responses of the host itself (reviewed in [Gerber and Nau, 2010]).  
In order to investigate the molecular mechanisms of cell modifications in the context of 
pneumococcal meningitis, the present study used primary rodent astrocytes (mainly deriving 
from mouse brain), and disease-relevant concentrations of pneumolysin, which is a key 
virulence factor of S. pneumoniae, as its presence, amongst other various effects, aggravates 
the clinical course of meningitis [Hirst et al., 2008; Hirst et al., 2004]. 
Structural studies, which normally use up to 100-fold higher concentrations of PLY (~ 
10 µg/ml), focus on the pore formation and lytic capacities of the toxin, inducing destruction of 
cells (hemolysis) or liposomes [Berry et al., 1995; Bonev et al., 2000; Gilbert et al., 1999; 
Tilley et al., 2005]. These concentrations, however, have no relevance in disease-related 
studies (≤ 0.18 µg/ml pneumolysin can be detected in the liquor of meningitis patients [Spreer 
et al., 2003]). 
Meningitis is a disease mainly affecting newborns, children younger than 5 years of age 
(indicated in Fig. 3), and immune-suppressed patients. Thus, in order to investigate neuronal 
cells in a disease-relevant state of development, newborn mice (p 3-5) were chosen for the 
isolation of astrocytes from brain tissue. 
The astrocytic nature of those cells was confirmed by fluorescent staining with a specific GFAP 
antibody. The glial fibrillary acidic protein (GFAP) is the principal intermediate filament in 
mature astrocytes and is widely used as a marker for the identification of cells in nervous 
tissue, and especially for the immunocytochemical/and -histochemical detection of astrocytes 
(reviewed in [Eng et al., 2000; Sofroniew and Vinters, 2010]). 
Although GFAP cannot be considered as an absolute marker, as it is present in most, but not 
all astrocytes, it could be detected in a wide range of the cultured cells (Fig. 25). The presence 
of neurons in the cultures could be generally excluded, as culturing of those cells requires 
special and well-adapted media, whereas the astrocytes are able to grow in D-MEM, 
supplemented with serum (FCS). However, the investigation was set to be limited to 
astrocytes, and thus the presence of large numbers of other brain tissue components, such as 
fibroblasts, had to be excluded.  
The star-shaped phenotype, which was already realized by Ramon y Cajal and del Rio Hortega 
in 1909, occurred also in the fluorescent GFAP staining (Fig. 25). They described two different 
subtypes of those glial cells, the protoplasmic astrocytes of the gray matter, which show a 
morphology of several stem branches that give rise to many finely branching processes, and 
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the fibrous astrocytes of the white matter, which exhibit a morphology of many long fiber-like 
processes [Ramon y Cajal, 1909]. 
In a previous study the liquor of patients suffering from acute pneumococcal meningitis was 
tested for its toxin load, and CSF (cerebrospinal fluid) concentrations of PLY were found to 
range between 0.001 and 0.2 µg/ml [Spreer et al., 2003]. As this study used in vitro 
experiments (cell-based or biochemical), and not in vivo conditions, applicable concentrations 
of PLY had to be determined. Those concentrations were extrapolated to be disease-relevant, 
as well as they were supposed to reveal a sub-lytic behavior to the cells, as the aim was to 
investigate the effects of PLY in the absence of cell death. 
Challenging primary astrocytes with concentrations of PLY between 0.05 and 0.5 µg/ml 
revealed cell permeabilization of 5% at 0.05 µg/ml, and 50% at 0.5 µg/ml, respectively, as 
judged by propidium iodide (PI) staining. At 0.1 µg/ml (disease-relevant concentration) only 
about 10% of cells were lysed (Fig. 26). However, the amount was sufficient to remodel the 
cell shape and to induce displacement of astrocytes. Many of the PI-positive cells were 
identified as microglia, which could be distinguished from the astrocytes by cell shape and size, 
and as they localize on top of the astrocytic cell layer [Squire, 2003]. These results enabled to 
define concentrations of 0.1 - 0.2 µg/ml of PLY as sub-lytic to non-lytic, comparable with the 
CSF concentrations of toxin in the liquor of patients [Förtsch et al., 2011]. Thus, under “sub-
lytic” we defined the conditions, in which only a small portion of cells would lose their integrity 
(~ 5%), while the cytoskeleton cell shape effects would be visible in most of the surviving 
cells. Dependent on the toxin batch, each of which contained different amounts of active PLY 
monomers, the concentration was adjusted to correspond to an identical level of lytic units. 
The challenge of astrocytes with 0.2 µg/ml pneumolysin led to very distinct cell shape changes 
and cell displacement. The contraction of the cell bodies induced the disruption of the cell 
monolayer, established by astrocytes when they are cultivated in vitro (Fig. 28). The 
displacement could be divided into an early phase with strong changes and a late phase with 
less severe changes, as shown in Fig. 29. The movement of the PLY-treated astrocytes could 
be distinguished clearly from the slight cellular fluctuations of quiescent cells, and thus clearly 
be assigned to as effects induced by PLY. Plasma membrane staining with GFP revealed that 
the cells kept attached to the bottom during their displacement (Fig. 32, Fig. 33), confirming 
that they were alive and that the shape changes were not due to cell death. Fluorescent 
staining of vinculin (a protein-component of focal adhesions, FAs) uncovered an increase in 
number and size of FAs upon toxin treatment (Fig. 31), which is conform to a model that 
describes the relation between adhesion and motility [Murphy-Ullrich, 2001]. The presence of 
defined focal points in astrocytes under untreated conditions indicates a capacity of motility. 
The displacement and retraction effects, followed by a less motile phase, accompanied by 
increased adhesion as witnessed by the progression from focal points to focal adhesions, fit 
very well with the concept of a transition from intermediate to strong adhesion separated by a 
mobile step (as discussed in [Förtsch et al., 2011]). The cell shape changes were accompanied 
by the appearance of nuclear outlining, which uncovered the roundish structure of the cell 
nuclei, which are normally not clearly visible during bright field, light microscopy (depicted in 
Fig. 28). This phenomenon is likely to be linked to the cytoskeletal changes occurring during 
displacement, which include cellular tensions, and which are also connected to actin 
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remodeling (indicated in Fig. 9). Normally most of the astrocytes are quite static cells, which is 
a prerequisite for their supportive function in the brain (see the introduction). Thus the 
occurrence of strong cell displacement induced by PLY, although not untypical, is clearly not 
common for the astrocytes. 
Each of the described effects, shape-changes, displacement via active movement (as recently 
reviewed by Anne Ridley [Ridley, 2011]), and establishment of focal adhesions are exclusively 
dependent on the actin cytoskeleton [Murphy-Ullrich, 2001], and the capacity to rapidly move 
is a defining feature of animal cells [Ridley et al., 2003]. Actin filaments are the basic units of 
cell locomotion. Disassembly of those filamentous structures by the use of cytochalasin D 
clearly showed a dependency of the PLY-induced effects on a functioning actin treadmilling 
apparatus, as the lack of actin structures abolished virtually all cell shape modifications, except 
the formation of membrane blebbings (Fig. 28 C), which in contrast were more abundant in 
the presence of CytoD (Fig. 32). Cytochalasins are fungal metabolites (CytoD is deriving from 
Zygosporum mansonii) and inhibit actin polymerization by high-affinity binding to the growing 
ends of actin filaments, preventing the addition of monomers [Casella et al., 1981]. This 
explains the inhibition of actin filament generation, which also prevents the rebuilding of the 
actin cortex below the membrane, and thus the retraction of the blebs. The altered phenotype 
of the astrocytes after cytochalasin pretreatment, and the lack of motility (Fig. 32) derive from 
the cytoskeletal destruction as well. 
Membrane blebbings are classically a feature of apoptosis (programmed cell death), and occur 
when the plasma membrane detaches from the actin cortex, which is anchored directly to the 
plasma membrane (PM). Increasing osmotic and onkotic pressure leads to a protrusion of the 
PM. In case of apoptotic membrane blebbings, the cortex rebuilds at sites of remaining actin 
structures, leading to a retraction of the PM after a short time interval (about 30 seconds). 
Furthermore, the apoptotic blebbings occur late in the progress of the cell death, normally 
hours after the initial pathogenic insult (reviewed in [Charras, 2008]). In contrast to these 
apoptotic blebbings, the ones observed after toxin-treatment of astrocytes did not show any 
signs of retraction, but the protrusions remained present over the whole time course of the 
experimental procedure (Fig. 32). This can only be explained with an ability of PLY to inhibit 
the rearrangement of actin below the plasma membrane, which can be achieved by a 
stabilization or severing capacity of the toxin. Live cell experiments with LifeAct-TagRFP-
stained actin and PLY-Atto488 indicated a similar action of pneumolysin, as the actin cortex 
showed a rapid detachment of the membrane and retraction in direction of the cell core (Fig. 
30 A). The position of the PM was witnessed by the fluorescent punctate clusters, which were 
aggregating on the top of the cells and maintaining their position even when the actin had 
detached. These dots represented most probably toxin aggregates, which seemed to promote 
severing of the actin cortex, following membrane binding and pore formation. 
These rapid events after toxin application reveal striking similarity in the mode of action 
between pneumolysin and the cellular actin effector gelsolin. Gelsolin was identified as one of 
the most potent actin filament severing proteins. Severing is mediated by the weakening of 
non-covalent bonds between actin molecules within one filament in order to break the filament 
in two. After severing, gelsolin keeps attached to the barbed end of the filament as a cap, 
which results in short filaments that can neither reanneal, nor be further elongated at their 
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barbed ends. The generation of such short filaments can, on the one hand, result in the 
disassembly of the actin cytoskeleton, although it can also have a constructive effect, as it 
increases the number of filaments with polymerization-competent ends, as soon as gelsolin 
dissociates from the elongation sites (the properties of gelsolin are reviewed in [Sun et al., 
1999]). One could speculate that PLY severs actin filaments from the PM, which induces the 
collapse of the cortex, and thus increases the number of barbed ends, which in turn provokes 
actin polymerization, possibly even at more or less adjacent sites, as specified further down. 
This is consistent with the transformation of actin fibers to an actin mesh, as shown in Fig. 33. 
Interestingly, the detachment of actin from the PM occurred in a horizontal direction, meaning 
laterally in direction of the cell core, whereat the actin cortex on top of the cells maintained its 
attachment (Fig. 30 B). This phenomenon can be easily explained with biomechanics, as it is 
known that the highest impact of tensions occurs at the sides of the cell, whereas the impact 
of vertical tensions is much lower. This might lead to an instability of the whole actin 
cytoskeleton scaffold as soon as PLY exerts its interfering actions at places where dragging 
forces are highest [Pourati et al., 1998]. 
Although LifeAct is very suitable for the visualization of actin structures in eukaryotic cells, it 
comprises a relatively new approach. Thus, it was necessary to confirm the results that were 
achieved with this system with a more reliable and established approach. Transformation of 
astrocytes with the pTagRFP-actin vector revealed similar actin changes in the astrocytes 
treated with PLY, compared to the LifeAct transfected cells, namely a decrease in actin network 
density and a general conversion of actin structures (Fig. 33). 
Calcium influx is a potent activator of GTPases, such as RhoA [Rao et al., 2001] and Rac [Price 
et al., 2003], and is often involved in the induction of cellular shape changes or cell death. PLY 
can induce early calcium influx [Stringaris et al., 2002], which might lead to the modulation of 
actin dynamics [Evans and Falke, 2007]. Therefore, the astrocytes were challenged with PLY in 
calcium-free buffer. In these experiments the concentrations of the toxin had to be adjusted 
due to earlier findings that PLY had an increased lytic capacity under calcium-free conditions 
[Wippel et al., 2011]. Even in the absence of extracellular calcium, pneumolysin still retained 
its capacity to produce rapid cell shape changes in astrocytes (Fig. 34), proving the 
independence of the observed effects on calcium influx. 
Cell modifications by bacterial toxins are often related to changes of the actin cytoskeleton, 
whereat the modulation results from direct or indirect modification of the cytoskeletal 
apparatus through covalent or non-covalent mechanisms (reviewed in [Barbieri et al., 2002]). 
One common non-covalent, indirect mechanism of those toxins is the modulation of small 
GTPases.  
Small GTPases are molecular switches that cycle between an on-state when bound to ATP and 
an off-state when bound to ADP. Subcellular signaling events, mainly arriving from the exterior 
of the cell, lead to activation of GEFs (guanine nucleotide exchange factors) or GAPs (GTPase 
activating proteins) and thus directly influence the status of the switch by controlling the 
nucleotide load (for further review see [Ridley, 2001]. The small GTPAses Rac1 and RhoA are 
the two main regulators of the actin cytoskeleton [Aspenstrom et al., 2004], being responsible 
for pushing cells forward by establishment of lamellipodia at the front and contraction of stress 
fibers, which reach throughout the cell body. The two proteins have many more functions in 
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the context of cell behavior, and the findings that sub-lytic concentrations of pneumolysin 
induced simultaneously an upregulation of Rac and Rho, and cytoskeletal rearrangement, were 
the cornerstone of this work [Iliev et al., 2007].  
However, neuroblastoma cells, applied in the initial phase of studying PLY effects, comprise a 
tumor cell line, and thus results can vary or be less relevant to the in vivo situation. In order 
to better understand the effects of pneumolysin in the physiological context of meningitis, and 
to gain more stable and reliable results, this study used primary astrocytes. Astrocytic 
cultures, however, are mixed cultures with microglial cells, another cell type of brain tissue. 
Microglia are immune-active cells, originating from the monocyte/macrophage line and sharing 
similarities with the macrophages, the Kupffer cells in the liver and the mesangial cells of the 
kidney. Microglia use the astrocyte syncytium to crawl upon in order to reach infected areas of 
the brain (Tambuyzer et al. give a more detailed insight into the potential of microglia 
[Tambuyzer et al., 2008]). This property explains their high grade of motility, which always 
involves a high grade of activated GTPases [Ridley, 2001]. Thus, for the investigation of RhoA 
and Rac1 activation in astrocytes, it was necessary to reduce the number of microglia in cell 
culture by shaking them off the astrocytic layer and removing the microglia-containing 
medium. Nevertheless, a high number of those cells remained among the astrocytes. This had 
to be taken into consideration by evaluation and interpretation of the results of pull down 
assays (Fig. 35 A), as these experiments produced highly variable results. Furthermore, it had 
to be considered that the activation of Rac and Rho in cells is strictly regulated. Upregulation 
of Rac leads to downregulation of Rho and vice versa (as indicated in [Wong et al., 2000] and 
[Sander et al., 1999]). This further complicates the measurement of activated Rho family 
proteins. Finally, the compartmentalization of the GTPase response remains largely impossible 
to analyze. 
To approach this problem, and to get further confirmation of the results of the pull down 
assays, a specific Rac1 inhibitor and a general Rho inhibitor were applied to the astrocytes and 
the cells were imaged, whereat the observed effects could be directly assigned to the 
astrocytes. Both approaches, however, showed, that Rac1 and RhoA were not involved in the 
primary effects (within 5 minutes) induced by sub-lytic concentrations of PLY. The pull down 
assays showed Rac and Rho activation at 5 minutes, with a maximal activation after 15 
minutes. The cellular changes were already observed after a few seconds upon toxin 
application, and the inhibitors had no capacity to reduce the displacement of cells in the early 
stages. These findings and the very rapid occurrence of changes indicate that both GTPases 
more likely play a secondary role in the effects induced by PLY. The Rac inhibitor reduced the 
displacement of cells in the late phase between 5 and 30 minutes, which is in accordance with 
Rac1 activation after 5 minutes displayed by the activation assays. The relatively late 
activation of Rac1 and RhoA thus indicates that, if there is no primary involvement, the late 
activation could display the attempt of the cell to re-establish the proper functioning of the 
cytoskeleton. If the toxin leads to a certain cytoskeletal disturbance, the cell will use its 
capacities to restore the original conditions. In cardiomyocytes, mechanical stretching, which 
also includes an interference with cytoskeletal integrity, induces Rac1 and RhoA activation in 
an actin-dependent manner, implying a link between primary actin alteration and secondary 
GTPase activation [Kawamura et al., 2003]. Alternatively, small GTPase activation by PLY 
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could occur independently of actin remodeling, e. g. via lipid raft interference. Lipid rafts seem 
to be critically important for proper targeting and activation of small GTPases [del Pozo et al., 
2004]. PLY interference with membrane cholesterol (e.g. clustering) [Bonev et al., 2000; Iliev 
et al., 2007] might additionally modulate small GTPases. 
The rather late activation of Rac1 and RhoA, following the rapid effects induced by PLY, implies 
a primary independence on these signaling pathways and thus points to a direct mechanism of 
action of pneumolysin on the actin cytoskeleton.  
In this context, PLY could possibly interact either with actin directly or through the activation 
or inhibition of (an) actin effector(s), or through interacting with both actin and an effector in 
an interconnecting manner. 
A certain affinity of the toxin to actin became clear in live cell imaging experiments, which 
displayed Atto488-tagged PLY, positioned on the membranes of cells in intimate proximity to 
the actin bundles below the PM. This phenomenon of actin bundle decoration was found at the 
very early time points after PLY application (within the first 30-60 seconds), and could mainly 
be observed on top of the cells, whereas lateral binding led to rapid cortex collapse induced by 
biomechanical tensions (as described above). 
Biochemically, the interaction between actin and a possible actin-binding protein can be 
investigated with the help of co-sedimentation assays. PLY could be detected in the pellet 
fraction together with actin. The presence of the toxin in the pellet, however, indicated a direct 
binding to the actin filaments. Furthermore, all variants of PLY had the capacity to co-settle 
with actin, whereat the wild-type toxin showed the strongest co-sedimentation, and revealed a 
capacity to slightly stabilize or polymerize actin, indicated by a shift of the actin ratio in 
direction of F-actin (Fig. 38). Slight stabilization/polymerization of actin could also be observed 
in actin-pyrene assays, when actin was incubated together with pneumolysin in absence of any 
other actin-polymerizing factors (Fig. 39). These findings clearly pointed to a direct influence 
of PLY on actin, confirmed by the fact that the actin polymerization was increased by the toxin 
in a dose-dependent manner (Fig. 39). 
Stabilization of actin includes the establishment of an equilibrium, in which actin monomers 
assemble and disassemble from a certain filament population in a similar ratio [Alberts et al., 
2008]. This indicates that PLY has either an influence on the pointed end of actin filaments 
where the monomers dissociate, or on the barbed end where the monomers are added to the 
filament. In the pyrene assays, stabilization is indicated by an increase of fluorescence, with a 
slightly higher maximal fluorescence rate than the fluorescence observed when actin nucleates 
spontaneously. The presence of ATP and magnesium is prerequisite for spontaneous 
dimerization of actin monomers (Fig. 7). The probability, however, that these dimers bind a 
third monomer, which is the critical step leading to polymerization, is lower than the 
probability that the dimer dissociates again. The binding of a third monomer increases the 
probability of successful nucleation and polymerization. The stabilization of actin dimers could 
be a possible point of attack for PLY to influence actin treadmilling [Alberts et al., 2008]. 
Pneumolysin settled together with the cytoskeletal components of astrocytes in a cytoskeleton 
isolation assay. Interestingly, when actin or tubulin, or both components were depolymerized 
by chytochalsin D, or nocodazole, respectively, the amount of PLY in the pellet decreased, 
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additionally pointing to a capacity of pneumolysin to bind actin filaments, and eventually 
tubulin structures, too. 
Actin affinity was also preserved when actin was partly degraded, indicated by the binding of 
PLY to actin in Far Western Blotting (overlay blot) experiments (Fig. 40) [Alberts et al., 2008; 
Hall, 2004]. The capacity to bind not only to actin filaments (F-actin), but also to monomeric 
actin (G-actin) was displayed by enzyme-linked sorbent assays (ELSAs) (Fig. 41). 
Even though this compilation of findings clearly demonstrates the capacity of PLY to interact 
with actin, both in cells, and within a biochemical background, it appears unlikely that a 
stabilization or slightly polymerization capacity would be sufficient to lead to the strong cellular 
modifications induced by the toxin.  
In vivo and in vitro, the VCA-domain of WASP family proteins is a critical activator of the Arp 
complex, which in turn is a very potent activator of de novo actin nucleation. VCA-activated 
Arp induces a fast and strong actin polymerization [Machesky and Gould, 1999; Rohatgi et al., 
1999].  
Actin-pyrene polymerization assays revealed a clear potential of PLY to enhance actin 
polymerization through the activation of Arp, even in the absence of VCA (Fig. 46, Fig. 48). 
This finding implied that both proteins are able to interact with each other. Similar 
experimental setups that were used to investigate PLY-actin interaction (ELSA, imaging of 
fluorescently labeled proteins) showed that pneumolysin was able to potently bind Arp2 of the 
Arp complex, and that PLY and Arp2 co-localized in primary astrocytes in close proximity, and 
partly overlapping (Fig. 43, Fig. 44). Arp is a stable heptameric protein complex, thus 
revealing multiple binding-sites for different interaction partners [Kelleher et al., 1995; Mullins 
et al., 1997]. While Arp2 [Rouiller et al., 2008] or Arp3 [Boczkowska et al., 2008] bind to VCA 
and actin, PLY had high affinity to Arp2, which suggests a bridging function of the toxin 
between Arp2 and actin. This in turn could explain the actin polymerization capacity of PLY in 
presence of Arp and absence of VCA (Fig. 46). 
The imaging of actin-rhodamine filaments revealed a similar actin phenotype, when Arp2/3 
was activated with PLY and with VCA. This additionally indicates, that PLY can activate Arp in a 
VCA-like manner, inducing the typical actin branching, that is also seen in the lamellipodia of 
moving cells, indicated in Fig. 12 [Heasman and Ridley, 2008]. 
Additionally, in the presence of VCA, PLY led to an enhanced actin nucleation and 
polymerization (Fig. 47), which indicated cumulative effects of the two components, and 
suggests that PLY binds to a different Arp subunit as VCA, instead of competing for the same 
binding site (indicated in Fig. 55).  
In the context of actin remodeling effects and active cell motility, in which the cells must direct 
actin assembly with a high degree of spatial and temporal resolution in response to 
extracellular signals, Cdc42 (another member of the Rho protein family) is suggested to be 
linked to actin polymerization over N-WASP and Arp2/3 [Rohatgi et al., 1999]. However, it has 
been shown before that pneumolysin does not increase activation levels of Cdc42 in 
neuroblastoma cells [Iliev et al., 2007], nor could an activation of this Rho protein be observed 
in primary astrocytes (data not shown). The absence of Cdc42 in other experimental setups 
(GUV approach) further confirmed the independence of effects from this protein. 
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Bacterial protein toxins are widely known to target the actin cytoskeleton, either through direct 
modification of actin (polymerization, stabilization, nucleation, filament bundling, ADP-
ribosylation of specific actin residues) or through interaction with actin effectors (Rho proteins, 
Arp2/3) (reviewed in [Barbieri et al., 2002] and [Aktories et al., 2011]). Several bacterial 
effectors were found to activate the Arp complex und thus actively enhance actin 
polymerization, both in vitro and in vivo. ActA, a surface protein of Listeria monocytogenes is a 
very potent activator of Arp and leads to the formation of so called comet tails or actin clouds 
in the cytosol of the host cells. The bacteria keep associated to the built-up actin structures 
[Welch et al., 1997]. The RickA surface-protein of Rickettsia conorii leads to the formation of 
filopodia-like actin aggregations, similar to ActA via activation of Arp2/3 [Gouin et al., 2004]. 
Both effectors are surface proteins of obligatory intracellular bacteria. In this respect, they 
differ from pneumolysin, which represents a virulence factor of an extracellular bacterium and 
mainly known for its pore-forming properties.  
Pneumolysin is not known to be secreted into the host cell. Furthermore it is not known that 
the actin changes by PLY contribute to an intra-/transcellular movement. Some evidence 
exists, however, that pneumococci can be transported transcellularly [Mook-Kanamori et al., 
2011]. This study, however, clearly shows that the toxin has the capacity to interact both with 
actin and Arp2, which are cytosolic proteins. Thus, the question arose if a pore-forming toxin 
could overcome the membrane barrier in order to exert its functions on the cytosolic side. By 
using a biomimetic system (GUV approach), composed of a cholesterol-containing lipid-bilayer, 
actin, Arp2/3, magnesium, ATP and PLY, the question could easily be approached. The setup 
did not contain any “interfering” components, such as GTPases or VCA. Therefore, direct 
effects of the toxin could be uncovered. PLY-GFP was delivered to the GUVs with the help of a 
lipid carrier. The complete free extracellular toxin was inactivated with the help of a cholesterol 
trap, and the proper orientation of PLY-GFP on the membrane was additionally confirmed with 
the help of the fluorescent quenching properties of trypan blue. The extra-vesicular suspension 
contained only the fluorescently labeled actin, the Arp proteins, magnesium and ATP. Actin has 
the capacity to aggregate spontaneously in the presence of the two latter factors, which could 
be observed in the suspension containing “blank” GUVs. The actin aggregations around the 
PLY-GFP loaded GUVs, in contrast, clearly derived from PLY impact on actin, as highest 
aggregations of actin-rhodamine co-localized with the highest aggregations of PLY-GFP (Fig. 
36).  
During the pore-formation process, every monomer of PLY unfolds its domain 3, resulting in 
penetration of the bilayer by four β-sheets of each monomer. In the unfolded conformation, 
the length of one PLY molecule is more than 12 nm [Tilley et al., 2005]. The thickness of the 
membrane is about 2.5-7.5 nm. Thus, the unfolded domain 3 could easily interact with the 
actin cortex below the plasma membrane, or with the Arp complex, which is sequestered and 
accumulated at the place of actin assembly. This hypothesis was consistent with the findings, 
that the Δ6 mutant of PLY, which is unable to unfold its domain 3 properly and thus to 
penetrate the membrane, could not aggregate actin to the same extent as the wild-type toxin. 
The usage of proper controls (mock, Δ6 mutant) also diminished the possibility that membrane 
curvature could induce actin aggregation. This had to be ruled out as possible factor, as in the 
GUVs actin and PLY take opposite positions as in living cells. 
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Cholesterol clustering by PLY [Bonev et al., 2000] should also be excluded as actin-
sequestering factor, because there is no evidence for a direct interaction between actin and 
cholesterol so far. 
As pneumolysin binds to the membrane and is not delivered into the host cell, only the 
unfolding-domain or parts of it would have the capacity to interact with cytosolic components. 
Following the finding that pneumolysin has the capacity to overcome the PM barrier by 
unfolding of domain 3, the dependence on this structural feature needed further investigation. 
The availability of variants/non-pore forming mutants (W433F [Korchev et al., 1998], Δ6 
[Kirkham et al., 2006]) and fragments (D123, D4) of the toxin allows further research on the 
dependence on pore-formation [Förtsch et al., 2011], and possible binding sites for interaction 
with other proteins. 
Enzyme-linked sorbent assays (ELSAs) revealed decreased binding affinity of the membrane-
binding domain 4 and the pore-formation deficient mutant Δ6 both to actin and to Arp2 (Fig. 
49, Fig. 50), consistent with the estimation that proper unfolding would be essential for 
interaction, and that the binding domain would have no binding capacity as its affinity is 
destined for cholesterol in the membrane [Baba et al., 2001]. The unfolding domain (D123) 
fragment alone and the WT-toxin, in contrast, biochemically showed high affinity to actin and 
Arp. These findings strongly point to domain 3 as interaction partner with the intracellular 
proteins.  
The unfolding domain itself consists of six polypeptides, incorporated in the 4 β-sheets that 
penetrate through the bilayer (Fig. 51). In this work, single peptides were used to reveal 
possible interaction sites of the domain and actin/Arp. Therefore, the fragments of domain 3 
were localized and commercially synthesized (Fig. 51). In actin-pyrene polymerization assays, 
the application of the single peptides, in addition to PLY, would either diminish or increase 
actin polymerization effects, either through competition of the peptide with the complete toxin 
molecule for the binding site within the actin or Arp molecule, or through additive effects, 
respectively. As none of the peptides led to significant changes of the normal activation grade 
induced by PLY (Fig. 52), one can speculate that none of the single peptides had the capacity 
to induce the effects alone. So either multiple segments are needed, or only the complete, 
properly functioning molecule can induce the effects. 
Concluding, these findings clearly reveal domain 3 as the actin/Arp-binding structure, whereat 
it is not yet clear, if single binding sites in the protein domain exist, or if the domain as a 
whole is essential for the interaction and the resulting effects. 
FRET (fluorescence resonance energy transfer) experiments with PLY-Atto488 and phoalloidin-
Alexa555 as FRET pair provided further insight into the structural characteristics of the PLY 
molecule. Phalloidin is one of the most specific actin binding chemical toxins [Wulf et al., 
1979], and has been found to also interact with Arp2 and weaker with Arp3 [Mahaffy and 
Pollard, 2008]. Considering the simultaneous affinity of PLY towards actin and Arp2, it was 
interesting to see if there would be phalloidin-specific binding sites on PLY. Indeed, the 
increase of phalloidin concentration led to quenching of PLY-Atto488 fluorescence, indicative of 
the presence of FRET. FRET (Fluorescence resonance energy transfer) occurs within a 
molecular distance of 5 nm, indicative of proximity,  and thus coherent with direct interaction 
[Kenworthy, 2001].  
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These findings propose that PLY, together with actin and Arp2/3 seem to represent a group of 
molecules, processing similar and complementary binding surface domains. 
In a final experiment, the role of the PLY/Arp interaction on the capability of PLY to form lytic 
pores was examined. To avoid the interference of cell trafficking phenomena on the toxin‟s 
lytic capacity [Idone et al., 2008], we utilized a system that is devoid of endo-/exocytotic 
events, namely - erythrocyte ghosts (depleted of ATP, and all other cytosolic components, too) 
and resealed after lytic emptying. The emptying and resealing of the ghosts made cytoskeleton 
remodeling (energy-dependent phenomenon) impossible, too [Schriei et al., 1975], thus 
practically limiting completely the cytoskeleton remodeling effects of Arp. The lytic capacity of 
PLY in calcein-loaded Arp2/3-enriched ghosts [Prausnitz et al., 1993] was higher than in IgG-
enriched or mock ghosts (Fig. 54). 
Although the role of other molecules, associated with the membrane as intermediates between 
PLY and Arp2/3, cannot be excluded completely, the high affinity of the pore-forming domains 
to Arp2 and the GUV experiments suggest a direct interaction. Earlier works confirm that only 
a portion of the whole CDC load on the membrane forms lytic pores [Morgan et al., 1994; 
Morgan et al., 1995], as the exact factors, determining the transition from prepore to pore still 
remain elusive. The findings point to a possible capacity of PLY to “hijack” the Arp2/3 complex 
to function as a scaffold, allowing better molecule alignment in pore configuration and thus 
enhancing the toxin‟s lytic capacity. The early co-localization between PLY-Atto488 and Arp2 
(Fig. 44) supports this concept. 
The changes in astrocytic shape and behavior, induced by pneumolysin provide the bacterium 
certain advantages while gaining access to the brain tissue. The effects of PLY, such as the 
induction of brain edema, alter the properties of brain tissue and open up spaces that allow 
deeper penetration into the brain of the host, and also facilitate the entrance of toxic 
macromolecules. Thus, the investigation of molecular mechanisms of the toxin effects are of 
major importance [Hupp et al., 2012]. 
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5 CONCLUDING REMARKS 
This work had the aim to investigate the molecular initiation mechanisms of cytoskeletal 
effects induced by disease-relevant concentrations of pneumolysin, based on the findings in 
neuroblastoma cells, that sub-lytic toxin concentrations led to cell modifications that were 
based on cytoskeleton remodeling [Iliev et al., 2007; Iliev et al., 2009]. The concentrations 
used in structural biology studies of PLY, describing the formation of macro pores and lysis, 
were about 100-fold higher (3-10 mg/ml) and not physiologically relevant [Gilbert et al., 1999; 
Morgan et al., 1995]. A PLY concentration of 0.2 µg/ml (comprising an equivalent amount of 
active toxin molecules in comparison to the more cytotoxic first charge of PLY) was determined 
to be sub-lytic on primary astrocytes in culture.  
The application of such amounts of toxin led to rapid cell shape remodeling, associated with 
shrinking, non-apoptotic membrane blebbing, and development of focal adhesions (FAs) from 
distinct focal points. The cellular changes resulted in monolayer disruption and cell 
displacement. All effects could be considered non-lytic, since the observed cells retained intact 
membranes (as judged by propidium iodide staining). The course of displacement was divided 
into an early phase with strong displacement, followed by continuing but slower changes.  
A very suitable method was established in order to use the displacement as indicator for toxin 
effects. The cell borders were tracked throughout a time stack with the help of the ImageJ 
“manual tracking” plugin, and the length of displacement was determined. 
Cytoskeletal destruction with cytochalasin D did clearly diminish cell movement upon PLY 
treatment, the lack of extracellular calcium, however, did not influence the effects, suggesting 
actin as a possible responsible factor. The small GTPases Rac and Rho were found to be not 
activated during the early time points of cell movement, and inhibition of the GTPases was not 
capable of extinction of the effects, proposing that they were not primarily involved in the 
effects induced by PLY. Late upregulation of Rac and Rho (5-15 minutes after toxin challenge) 
pointed to a repair mechanism attempt of the cell to re-establish proper cellular function. 
A close look (high-resolution z-stack imaging) on the actin cytoskeleton with the help of 
LifeAct-TagRFP actin staining revealed decoration of cortical actin bundles by PLY. The toxin 
assembled on the plasma membrane in intimate proximity to actin, and very rapidly led to an 
actin cortex collapse in direction of the cell core, while the toxin aggregates remained attached 
to the membrane. The actin collapse occurred exclusively in horizontal direction, where 
biomechanical tensions are highest. 
Several biochemical approaches revealed an affinity of PLY to actin, as most in vitro 
experiments pointed to an actin stabilization capacity of PLY, in contrast to the actin 
severing/degradation events visible in the imaging approaches. Taking in consideration that 
even cellular actin effectors, such as gelsolin, on the one hand sever, and thus disassemble 
actin, and on the other hand polymerize actin, by generation of new polymerization-competent 
ends, these two PLY-induced effects do not exclude each other. The toxin possibly severs actin 
at the lateral binding sites of cells, and thus provokes actin polymerization at different sites. 
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The biomimetic GUV (giant unilamellar vesicle) approach used a limited set of factors, namely 
the toxin, actin, and Arp, separated by a lipid-bilayer to analyze PLY/actin effects. The wild-
type toxin had the capacity to aggregate actin on the opposite site of the membrane in 
presence of the actin nucleation factor Arp. The amount of actin clusters was significantly 
higher than the actin aggregations that occurred spontaneously around the vesicles loaded 
with the non pore-forming mutant Δ6 or around unloaded vesicles. This confirms that PLY had 
the capacity to overcome the barrier comprised by a lipid-bilayer and was able to exert its 
effects on the other side, from a membrane-bound state. 
Similar to actin, PLY showed a strong affinity to Arp2 of the Arp complex, and similar to actin, 
the Δ6 mutant and the D4 binding domain showed low binding affinity to the Arp complex 
protein. 
PLY performed slight actin polymerization/stabilization, Arp activation, and synergistic Arp 
activation in presence of VCA in actin-pyrene polymerization assays. 
 
 
 
 
In conclusion, this study revealed novel capacities of pneumolysin that go beyond pore-
formation and induction of cell lysis. 
The toxin binds to cells, leading to cellular changes that are not associated with cell death. It 
overcomes the plasma membrane barrier by unfolding its domain 3, and directly interacts with 
the sub-membranous actin cortex and with Arp, which is accumulated in these actin rich 
regions. 
This study for the first time suggests direct interaction of a toxin of the cholesterol-dependent 
cytolysin family with submembranous molecular targets. 
The effects of sub-lytic amounts of PLY on primary astrocytes, which were uncovered in this 
work, led to the hypothesis that astrocytic process retraction, cortical astrocytic 
reorganization, and thus brain tissue remodeling would cause increased tissue permeability to 
toxic macromolecules and bacteria. This hypothesis was confirmed and additionally revealed 
 
Fig. 55: Schematic of actin 
nucleation activation. 
PLY activates Arp2/3 
synergically with the VCA 
domain of WASP by binding to 
the Arp2 portion of the 
complex. 
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an increased interstitial fluid retention in brain tissue, which is manifested as tissue edema 
[Hupp et al., 2012]. 
 
 
 
Fig. 56: Tissue penetration. 
Brain tissue remodeling by astrocytic process retraction and cortical astrocytic reorganization by PLY 
enables tissue penetration of bacteria and toxic macromolecules. 
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6 PERSPECTIVES 
In general, the investigation of molecular mechanisms of effects induced by bacterial effectors 
is aimed to get a better understanding of host-pathogen interactions and to possibly discover 
druggable targets that help to further development of prevention and/or treatment of 
infections. This work provides a basis for follow-up research in several directions.  
Future investigations, based on this work, will have to focus on the mechanistic clarification of 
PLY-Arp and PLY-actin interaction. As mentioned, this study for the first time proposes that a 
toxin of the CDC family can act from a membrane-bound state on intracellular actin effector 
proteins and actin itself. It is indicated here that the unfolding of domain 3 is essential for 
interaction. However, it has to be further clarified, which peptide structures are responsible for 
the interaction, and how PLY and the VCA domain collaborate to activate Arp and polymerize 
actin. Therefore the employment of multiple domain 3 peptides (in different combinations) 
might give further insight, as possibly not only single peptides, but eventually two or more 
peptides collaborate to induce actin stabilization or Arp activation, or bridge the interaction of 
both proteins, respectively. 
A closer look has to be taken on the mechanism of actin severing and membrane blebbing, 
which are possibly linked up. It will be interesting to investigate if the current hypothesis, that 
cortex severing from the PM and the associated increasing pressure lead to surface distortion, 
and that the actin stabilization hinders the re-establishment of the cortex, which would induce 
membrane retraction. 
The generation of Arp-knockout astrocytes could further clarify the importance of Arp in the 
effects induced by the toxin. Literature, however, does not present trials that were successful 
in knocking out this protein. The cells barely survive this approach. The commercially available 
Arp2 knock-out cell lines could be applied to gain further insight, although this approach would 
not sufficiently clarify the effects in context of brain infections. 
An animal model will be applied to investigate the potential of pneumolysin to break the blood-
brain barrier. Therefore a specific dye will be applied to the tail vein of newborn rats and 
distribution in the brain after toxin challenge will provide insight into this issue. 
Listeriolysin O (LLO) of Listeria monocytogenes and perfringolysin O (PFO) of Clostridium 
perfringens belong to the family of CDCs as well. It will be investigated if these toxins, which 
show high structural homology to PLY, exert the same effects on cells as PLY or if their effects 
differ from those of PLY. L. monocytogenes is not primarily inducing meningitis, but if those 
bacteria reach the brain, the formation of abscesses can be observed in the sub-meningeal 
cortex regions. This justifies the application of astrocytes and brain slices for investigation of 
the effects of LLO. C. perfringens is the main cause of food poisoning and gas gangrene. 
Although not related to meningitis, experimental setups with astrocytes and brain slices will 
comprise the first approach to gain further insight in the effects of this toxin in cell-based 
effects. 
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Abbreviations 
µg Microgram 
µl Microliter 
µm Micrometer 
µM Micromolar 
A/Ala Alanine 
APB Actin Polymerization Buffer 
Arp Actin Related Protein 
ADP Adenosine-5‟-diphosphate 
ATP Adenosine-5‟-triphosphate 
BBB Blood-brain Barrier 
BCA Bicinchoninic Acid 
BL Black 
BSA Bovine Serum Albumin 
C Centigrade 
Ca Calcium 
CaCl2 Calcium chloride 
CDC Cholesterol-dependent Cytolysin 
Cl Chloride 
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CNS Central Nervous System 
CSF Cerebrospinal Fluid 
Cy Cyanine 
CytoD Cytochalasin D 
d, dd Distilled, double distilled 
DABCO 1,4-Diazobicyclo-(2.2.2)-octane 
D-MEM Dulbecco‟s Modified Eagle Medium 
DNA Deoxyribonucleic Acid 
E. coli Escherichia coli 
EGTA Ethylene glycol tetraacetic acid 
ELSA Enzyme-linked Sorbent Assay 
EM Electron Microscopy 
F/Phe Phenylalanine 
FCS Fetal Calf Serum 
Fig. Figure 
FITC Fluorescein isothiocyanate 
FRET Förster/Fluorescence Resonance Energy Transfer 
g Gram 
g Gravitational Force 
GAB General Actin Buffer 
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GAP GTPase-activating Protein 
GEF Guanine Nucleotide Exchange Factor 
GFP Green Fluorescent Protein 
GDP Guanosine-5‟-diphosphate 
GTP Guanosine-5‟-triphosphate 
h Hour 
H2O Water 
HEPES 2-(4-(2-Hydroxyethyl)-1-piperazinyl)-ethanesulfonic acid 
HRP Horse Radish Peroxidase 
Ig Immunoglobulin 
K Potassium 
KH2PO4 Potassium Dihydrogenphosphate 
KCl Potassium chloride 
kDa Kilodalton 
l Liter 
LDH Lactate Dehydrogenase 
mA Milliampere 
magn. Magnification 
Mg Magnesium 
mg Milligram 
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MgCl2 Magnesium chloride 
min Minute 
ml Milliliter 
MOPS 3-(N-morpholino)propanesulfonic acid 
mV Millivolts 
n Sample Size 
Na Sodium 
NaCl Sodium chloride 
Na2HPO4 Disodium Hydrogenphosphate 
ng Nanogram 
NHS N-hydroxysuccinimid 
nm Nanometer 
nM Nanomolar 
p p-Value (probability value) 
p (3) Postnatal day (3) 
p(DNA) Plasmid (DNA) 
PAGE Polyacrylamid Gel Electrophoresis 
PBS Phosphate Buffered Saline 
Pen/Strep Penicillin/Streptomycin 
PFA Paraformaldehyde 
ABBREVIATIONS 
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PI Propidium Iodide 
PIPES Piperazine-N,N′-bis(2-ethanesulfonic acid) 
PLO Poly L-ornithine 
PLY Pneumolysin 
PM Plasma Membrane 
PVDF Polyvinylidene fluoride 
R/Arg Arginine 
RFP Red Fluorescent Protein 
rpm Revolutions per Minute 
RT Room Temperature 
S. Streptococcus 
s/sec. Second 
SD Sprague Dawley 
SDS Sodium dodecyl sulfate 
SEM Standard Error of the Mean 
TMB 3,3',5,5'-Tetramethylbenzidine 
TRITC Tetramethyl Rhodamine Iso-Thiocyanate 
V Volt 
v/v Volume per Volume 
ABBREVIATIONS 
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VCA Verprolin-homology-cofilin-homology-acidic (domain) 
w/o Without 
W/Trp Tryptophan 
(N)-WASP (Neuronal) Wiskott-Aldrich-Syndrome Protein 
WHO World Health Organization 
WT Wild-type 
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